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A STUDY ON USEFULNESS OF FLOW MEDIATED VASODILATATION OF BRACHIAL ARTERY 
IN ASSESSING THE SEVERITY OF CORONARY ARTERY DISEASE AND ITS CORRELATION 
WITH CORONARY ANGIOGRAM 
NARENDRAN.A1. K. TAMILSELVAN2. K. KANNAN3, STANLEY MEDICAL COLLEGE AND HOSPITAL, CHENNAI. 
1 – POSTGRADUATE MEDICAL STUDENT, 2 – ASST. PROFESSOR, CARDIOLOGY, 3 – PROFESSOR OF CARDIOLOGY, 4 – 
PROFESSOR OF MEDICINE. 
KEY WORDS : FLOW MEDIATED VASODILATATION, CORONARY ARTERY 
DISEASE, CORONARY ANGIOGRAM. 
SECONDARY OBJECTIVES 
1. TO ASSESS THE CORRELATION BETWEEN  OTHER WELL ESTABLISHED 
CARDIOVASCULAR RISK FACTORS LIKE SMOKING, WAIST HIP RATIO, LIPID 
ABNORMALITIES AND CAROTID INTIMA MEDIA THICKNESS. 
2. TO ASSESS THE RELATIONSHIP BETWEEN PER-CAPITA INCOME AND 
CAG CHANGES 
3. TO ASSESS THE RELATIONSHIP BETWEEN DIET PREFERRENCE AND CAG 
CHANGES 
MATERIALS AND METHODS 
PLACE OF STUDY: 
 DEPARTMENT OF CARDIOLOGY, CARDIOLOGY OPD, MEDICAL WARDS 
AND IMCU AT STANLEY MEDICAL COLLEGE AND HOSPITAL, CHENNAI. 
DURATION:JAN 2014 TO SEP 2014. 
STUDY DESIGN:RETROSPECTIVE OBSERVATIONAL STUDY 
SAMPLE SIZE: 75 
METHODOLOGY- 
Patients diagnosed with coronary artery disease within 1 month and have undergone 
coronary angiogram ;from the period January 2014 to September 2014 in ICCU/ 
cardiology wards are included in the study. Patients will be subjected to symptom 
analysis, clinical examination, laboratory investigations and flow mediated 
vasodilation studies of brachial artery. The final analysis will be made at the end of 
the study to achieve the fore mentioned goals using appropriate statistical methods. 
 
PATIENT SELECTION: 
INCLUSION CRITERIA 
1. All patients who have been diagnosed having coronary artery disease which includes 
chronic stable angina, ST elevation MI, non ST elevation MI , unstable angina 
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within the last 1month and have undergone CAG. 
2. All patients who have undergone primary/ facilitated PCI within the above mentioned 
time. 
3. Patients between 20 and 60 years of age. 
 
EXCLUSION CRITERIA 
1. Patients with any form of connective tissue disorder, chronic kidney disease, Chronic 
liver disease 
2. Any patient < 20 and > 60 yrs of age. 
 
CONCLUSION OF THIS STUDY 
Our aim of this study was to determine if there is any correlation between severity of CAD 
and FMD of the brachial artery , as well as to observe the relationship with various other 
cardiovascular risk factors . 
A total of  75 patients were included in the study and  following are  conclusions from the 
statistical analysis. The subjects were divided into 4 four study groups as described above and 
subsequently analysed. 
 The association between the study group and factors like age , gender , diet ,alcohol 
intake ,duration  of hypertension was found to have no correlation  
 There is a positive correlation between duration of smoking and severity of  CAD  
 Presence of diabetes had an meaningful correlation with the study groups and there is 
a increase in severity of CAD with increase in duration of diabetes 
 BMI was found to have a positive correlation with the study groups and as the BMI of 
the patient increased  more severe was the CAD observed in them 
 Non HDL (LDL) was found to be the better marker for assessing the cardiovascular 
risk as there was a significant increase in CAD severity with increasing levels of LDL 
,however no such positive correlation existed between study groups and HDL 
 Left ventricular ejection fraction measured at the time of admission was significantly 
lower as the severity of CAD increased  
 There was no positive correlation between  brachial artery resting diameter and post 
occlusive diameter among the various CAD groups 
 Interestingly percentage of  increase in flow mediated vasodilatation correlated well 
with the severity of CAD , in which the more severe CAD patients had significantly 
lower percentage increase in FMD 
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 There is also a meaningful correlation between   % increase in FMD and modified 
GENSINI SCORE.As the severity of CAD as assessed by modified GENISINI score 
increased significantly lower was the % increase in FMD. 
       
  Hence we conclude that apart from assessing the traditional cardiovascular risk 
factors , it is also important to assess the endothelial function of the patient by 
methods like FMD. It is very clear the physiological alteration(endothelial 
dysfunction)  in the body due to atherosclerosis, diabetes and other risk factors occur 
much before the structurally evident changes like plaques. FMD could be used as a 
tool to determine the endothelial function of the patients very early in the course 
natural history of CAD . Its use could be widely employed as it is non invasive and 
very simple procedure . Interestingly even unstable angina patients with normal /non 
obstructive CAG  had  endothelial dysfunction and whether this could be the reason 
for angina is still debatable. Since it a direct reflection of the health status of coronary 
vessels this could be utilised in screening of even young  healthy individuals with 
family history of CAD . This technique has great scope in the near future mainly 
because of its non invasive technique in assessing the severity of CAD. It however 
requires large sample studies to substantiate this and  though not yet recommended for 
routine clinical use, non invasive endothelial function testing has provided valuable 
insights into vascular changes associated with early atherosclerosis and the potential 
reversibility of arterial disease. 
 
 1 
 
INTRODUCTION 
 
 
FLOW MEDIATED VASODILATATION 
 
There is a lot of research study dedicated to observe vascular biology inhumans.  
The vascular endothelium is in a unparallel position to function as a  marker of  
risk of atherosclerosis . 
 The endothelium is a special tissue   that releases  numerous substance  that  
moderates tone of the vascular bed,  growth of cells  , platelet   and WBC  
interactions . The endothelium responds to variousinternal and external stimuli 
via complicated  receptors  in cell membrane and  mechanisms of signal 
transduction  , leading to the formation and discharge of various vascular active  
hormones  and factors. The ability of blood vessels to react  to physical and 
biochemical stimuli in the blood flow and circulation in response to changes in 
the local surroundings . Various blood vessels react to an amplification in flow 
or more accurately stress , by dilation.  This  process is defined as flow 
mediated vasodilatation.A primary mediator of FMD is nitric oxide derived 
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from endothelium . This  property of endothelium  could be used for risk 
evaluation . 
 
The finding  of nitric oxide (NO) as a vital  molecule forvascular relaxation and 
the detection of the endothelium as more than a passive inert medium  between 
blood and the vessel wall gave way to a significant  breakthrough  in vascular 
research. Endothelial dysfunction is a pathologicalprocess in which there is  an 
imbalance between factors with vasodilating, antimitogenic  properties and 
substances with  vaso-constrictive, prothrombotic properties . Among the most 
vital vasodilating  factors , chiefly in muscular arteries( is NO) whichalso slows 
down other key events inthe  progress of atherosclerosis such as platelet 
adhesion and aggregation, WBC  adhesion and migration, and  proliferation of 
smooth muscle cells.Importantly in the microcirculation, prostacyclin and other 
endothelium-derived growth factors  also execute an vital  role. 
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Usually , loss of NO bio function denotes  a widely dysfunctional  phenotype 
across endothelial properties . Hence, the evaluation of its vasodilating  property 
as a result of NO and  various other molecules could offer knowledge on the 
reliability and utility of the endothelium.Surprisingly, cardiovascular risk 
factors are related with dysfunction of endotheliumand risk factor alteration 
leads to enhancement in vascularfunction. Endothelial dysfunction has been 
found out  in the coronary epicardialand resistance vessels and in the arteries of 
periphery , so endothelial dysfunction could  be  considered  as a systemic 
condition. Significantly, the evolution  of atherosclerosis occurs much  early in 
life, and endothelialdysfunction accelerates  atherosclerosis  and occurs   much 
before  the development of morphological  changes in the vascular bed.The aim 
of our study  is  to give a short overview of the most commonly usedtechnique  
to assess  endothelial function in human beings, predominantly noninvasive  
methods, and to sum up the clinicalimportanceofendothelialdysfunction in the 
inhabitants and in person . The potentialoutlookof endothelial function 
quantification for  personalised medicine is alsoadvised. 
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Brachial artery flow-mediated dilation (FMD) has emerged as the 
most common assessment tool of endothelial function. This response 
is 
1) nitric  oxide dependent 
2)abnormal early in the course of the disease 
3)dysfunctional in response to various cardiovascular risk factors 
4)correlated with abnormalities of coronary endothelium-dependent  
vasodilatation    
5)improved with interventions known to improve cardiovascular 
outcomes such as STATIN therapy 
6)relatively inexpensive 
7)noninvasive 
8)reproducible 
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A disturbance of endothelial function is considered as akey event in 
the development of atherosclerosis, hypertension and heart failure. 
Thus reliable assessment of endothelial function in humans is fairly 
important. This can be achieved by different approaches. 
1) measurement of morphological and mechanical characteristics of 
the vascular wall ( intima media thickness, distensibility , compliance 
, remodelling indexes . 
2)determination of soluble endothelial markers ( Von-Willebrand 
factor , plasminogen activator ) . 
3)measurement of the endothelial dependant regulation of the 
vascular tone at focal sites of the circulation by flow mediated 
vasodilatation techniques (FMD) . 
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METHODS TO ASSESS VASCULAR     FUNCTION 
 
The first exhibition of endothelial dysfunction in atherosclerosed coronary 
arteries using  the technique of intracoronary infusion of  the drug acetylcholine 
and its subsequent  quantification of  coronary angiography was done by doctor  
Ludmer and his associates in 1986. Theirinfluentialstudy marked an significant  
shift of hypothesis in the perceptive ofatherosclerosis,  which was formerly been  
considered as a solely structural disease.This research drew interest  to the 
functional  features  of atherosclerosis such as increased  vasoconstriction as a 
result  of improperly functioning endothelium. Then , non invasive methods 
were designed using  the forearm circulation as a replacement for assessing 
coronary arteries. All techniques had their plus  and minuses , most essentially  
different vascular beds were examined 
The basic rule however was  similar ,  Healthy arteries  such as the  brachial  
and coronary arteries expand in reaction to reflex hyperaemia (which is nothing 
but flow-mediated vasodilatation) or following  pharmacological stimuli ,which  
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includes infusion of intra arterial  endothelium-dependent vasodilators such 
asbradykinin or  acetylcholine,  through  discharge of NO and other vasoactive 
substances. In disease condition , this  endothelium-dependent vasodilatation is 
either reduced or absent. However, regardless of  whichever  method  is applied, 
vascular responses are  governed not only by the functional status of the 
vascular bed  at the measurement positionbut also by theresistance 
arteriesstructural condition  in the micro vascular  bed .  
 
In addition, to distinguish response which are endothelium-dependent from 
endothelium-independent ones , exogenous donators of  NO such as glycerol-
trinitrate  or direct non–NO donators like  adenosine can be used. Improper 
endothelial-independent function is  however related more with structural 
vascular modifications and changes  in smooth muscles cells rather than  
alteration in the endothelium. 
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CORONARY EPICARDIAL AND MICROVASCULAR 
FUNCTION 
 
 
To measurethe function of coronary endothelium, a functionalanalysis is done 
to assess the endothelial function of epicardial and resistance vessels. Even 
though these techniques are restricted by its invasive nature, their benefit is to 
quantify endothelial function directly  in this vascular bed which is clinically 
important. 
 
EPICARDIAL ENDOTHELIAL FUNCTION 
 
To illustrate vasomotor reactiveness  of epicardial coronary arteries, quantitative 
CAG or intravascular high frequency ultrasound is performed, and alteration  in 
vessel thickness  and cross-sectional areas in reaction  to endothelium-
dependent interventions are recorded . Following infusion of  acetylcholine , 
vessels with integralendothelium vasodilate,but vessels  with non intact  
endothelium will react  with vasoconstriction as a consequence  of direct  
enhancement of muscarinic receptors which are present   on the  smooth 
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musclevasculature . Comparable induced functional alterations  in vascular 
reactivity have been established with salbutamol and other substances. Physical 
variables   like exercise or pacing-induced tachycardia as a equivalent  
forexercise can be considered endothelium derived response  which  cause  an 
amplification in coronary blood flow and  also increase the  stress on the 
coronary circulation, ultimately leading  to flow-mediated endothelium-
dependent vasodilatation  of the  vessels in the epicardium. Identical  changes 
can also  be observed  in reaction to mental stress. This study of flow-mediated  
vasodilatation in the coronary  vessels and its dysfunction  
inatherosclerosis gave away the idea to study identical  responses in the 
peripheral vascular bed . By using cold pressor test  which is a “physiological” 
test to gauge epicardial vessels vasoreactivityin which the patient puts her  or 
his  hand into ice cold  water and this leads to   sympathetic nervous system 
amplification which cause  NO release  and endothelium-derived 
hyperpolarizing substances  and consequently vasodilation in healthy 
vessels.But , in  case of endothelial dysfunction ,  vasoconstriction of smooth 
muscle cells will govern, identical to responses to acetylcholine. 
 11 
 
 
  
 12 
 
 
 
 
  
 13 
 
CORONARY MICROVASCULAR FUNCTION 
 
Variations  in myocardial  blood flow could be utilised  as a stand-infactor for 
micro vascularutility. Coronary  blood flow reserve is calculated  by  using the 
numerator as maximal coronary blood flow during maximal coronary 
hyperaemia  divided by the resting coronary blood flow. This optimal flow 
response process  is both endothelium- and non–endothelium-dependent, and a 
coronary blood flow reserve capacity ration <2.0 is taken as not normal.The 
quantification of  microvascular function   which is dependent on endothelium, 
the percentage rise in coronary blood flow in reaction  to vasodilators ( 
acetylcholine)  administered  at rising titre  is monitored.Numerous ways to 
quantify microvascular function have been used , examplewith proximal 
injection of contrast the amount of cineangiographic frames that will take  to fill 
a distal  most vessel is measured . The corrected Thrombolysis in Myocardial 
Infarction frame count provides a semiquantitative assessment of epicardial 
coronary blood flow. Taking the main disadvantage—the invasive nature of the 
above-mentioned tests—into account, noninvasive functional tests to assess the 
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coronary microvasculature have been developed, among them positron emission 
tomography, myocardial perfusion imaging, blood oxygen level–dependent 
magnetic resonance imaging, and echocardiography; however, a detailed 
discussion of these tests is beyond the scope of this review. 
 
FLOW-MEDIATED VASODILATION OF BRACHIAL 
ARTERY 
 
 
As a result of its noninvasive approach, flow-mediated vasodilatation of the arm 
arteries (FMD) has become the most widely used technique to measure 
endothelial function. The technique measures the ability of the arteries to 
respond with endothelial NO release during reactive hyperaemia (flow 
mediated) after a 5-minute occlusion of the brachial artery with a blood pressure 
cuff. Celermajer and colleagueswere the first to measure this response in vivo 
by measuring the respective diameter changes of the brachial or radial artery by 
ultrasound, a response later demonstrated to be mainly NO dependent, although 
other vasodilator pathways also may contribute. Importantly, peripheral 
endothelial function as assessed by FMD correlates with coronary artery 
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endothelial function.However, although the principle of this technique seems 
simple, its application is technically challenging and requires extensive training 
and standardization  . Study preparation, image acquisition and site selection, 
sphygmomanometer probe position, cuff occlusion time, accurate use of edge-
detection software, and correct characterization of the FMD response are 
crucial, as recently outlined in detail in guidelines by Charakida et al, Harris et 
al, and Thijssen et al. These publications are useful in that they draw attention to 
the need to standardize the different protocols; indeed, if efforts to standardize 
the technology are followed, reproducibility of FMD can be considerably 
improved. 
 An vital determinant  in the path physiology of systemic hypertension , 
atherosclerosis,  and cardiac failure was linked to endothelial dysfunction.  
High-frequency USG  image attainment  of the brachial artery vessel to gauge 
endothelium-dependent ﬂow-mediated vasodilatation (FMD) was established in 
the early 1990.  The vasodilatation observed is because of liberation of NO that 
is stimulated  in this technique and that could  be measured  as a marker  of 
vasomotor function. It is a very useful technique to swot up the efficiency of 
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various interventions that could influence the vascular endothelial function , as 
it is  non invasive and further allows repetitive measurements over time . There 
are other technical and interpretive restrictions of this technique in spite of its 
widespread use.  With new guidelines for its  application  in the field of research 
to study vascular  endothelial physiology and latest technologies which provide 
information , insights which strengths its application and reduce its limitations 
to make it effective in using high -resolution ultrasonography of  the brachial 
artery  to evaluate vascular endothelial function .The endothelium  is a special 
tissue   that releases  numerous substance  that  moderates tone of the  vascular 
bed,  growth of cells  , platelet and WBC  interactions  . The endothelium 
responds  to variousinternal and external stimuli via complicated  receptors  in 
cell membrane and mechanisms of signal transduction  , leading to the 
formation and discharge of various  vasoactive  hormones  and factors. 
Dysfunction  of the endothelium plays a vital role  in the progress of 
atherosclerosis, hypertension, and cardiac failure. In the last few years, a 
noninsidious method has  been developed to appraise  FMD  which is a process 
dependant on the  endothelium , in the brachial artery . This spur  activates the 
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cells of endothelium to dischargeof  NO with consequentdilation  which can be 
pictured  and used  as a marker  of vascular bed  function. Theprocedure is up-
coming  as  it is non-insidious  and makes way forrepetitive measuring options . 
Inspite of its prevalent usage , it has procedural and practical restrictions. Our  
study will focus on analysing and developing  this striking and buddingmethod. 
PHYSIOLOGY OF FMD 
The ability of blood vessels to react  to physical and biochemical stimuli in the  
lumen  enables the capability to self-regulate tone and to modify blood flow and  
circulation in response to changes in the local surroundings . Various blood  
vessels react to an amplification in flow or more accurately  stress , by  
dilation.  This  process is defined as flow mediated flow mediated vasodilation.  
A primary mediator of FMD is nitric oxide derived from endothelium .  
The exactphysiology for the immediate recognition  of  stress effects and its 
consequentimpulse transmission to alter the tenor of vessels is  not  totally 
explained . Specific ion channels that are present in the endothelial cell 
membrane like potassiumchannels that calcium dependant ,thatopeninresponse  
to shear stress forces . Hyperpolarisation of  the endothelial cell caused by 
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opening of the potassium channel ,  increases  the dynamic force for calcium 
entry  into the cells as there are no voltage- gated CA channels in endothelial 
cell membrane . This   activates an enzyme, endothelial nitric oxide synthase 
(eNOS), andtheconsequentproductionofNOseems to be responsible for  FMD . 
FMD can be impaired  in a range of arterial vessels when there is administration 
of inhibitor of the enzyme nitric oxide synthase (NOS)  
MEASURING FMD  IN HUMAN BEINGS: ANALYTICAL AND 
CURATIVE FEATURES 
Dysfunction of the endothelium  is indicated  by an improper  response in the 
FMD . In the vascular bed of human beings ,  forearm and coronary circulation 
are the ideal location to study FMD. Predominantly, a vasodilatation stimuli  is 
given to the vessels in downstream  there by picking up a ﬂow-mediated 
vasodilation of the vessel in upstream .  Doctor Celermajer and  his associates 
designed a distinctive method  to observe  FMD  non-insidiously  and 
consistently in  forearm vessels of human beings . Aenhancement  in  blood 
flow  into the brachial artery is achieved by  postischemicvasodilatation in the 
vasculature of the distal forearm. This can be caused by inﬂating a  B.P cuff 
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positioned over  proximal  part of forearm to pressure  above systolic blood 
pressure inducing  a ischemia in the vessels  distal to the cuff . When  the  
pressure of the cuff is liberated , a swiftaugmentation  of blood ﬂow through  
the vessels that were dilated . The succeedingamplification in  stress forces 
acting  in  upstream vessels  induce vasodilatation of  brachial artery, which can 
be evaluated using   an USG device . As the amount of cardiovascular risk 
associations  rise ,  more demonstrable is the endothelial  dysfunction . This has 
to be well thought-out while  we studysubjects  with  atherosclerosis of 
coronary or systemic vessels . Various stimulus intensely control   FMD: such 
as fatty meal and post-meal hyperlipidemia , stress, increased levels of 
catecholamine , high quantities  of oestrogen and progesterone , smoking , 
blood sugar changes and alterations in electrolytes .Sudden elevation  in stress 
levels that occur in dialysis have  been  noticed  , which could  be linked to 
impair  FMD  in brachial vessels .However this  the response of FMD seems to 
be non dependent from the  viscosity  of blood . Also , circadian rhythm 
alteration brings about changes in tone of vascular bed  is well documented. 
Therefore  FMD  is a very reliable technique that allows clinicians  to accurately 
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note the  endothelial function  alteration in human beings . In further  studies  
deciding curative interventions based on  functioning of endothelium , subjects 
should  be cross-matched and  standardized protocol must be developed for 
demonstrating  impact of various  factors on FMD.  The prerequisites about 
subject  choice and settingof study in assessment  of brachial vessel response 
holds  good to coronary circulation also. Vasodilatation of cardiac  resistance 
arteries  to bring about raise in  stress forces  in the  epicardial vessels can be 
fulfilled  by metabolic stimulus like physical exercise or stimulation of 
pacemaker . Instead, this can also  be achieved  by selectively infusing   drugs 
like adenosine    into the mid part of  epicardial vessels and concurrent 
measurement of FMD in the proximal most part  of the vessel  under 
examination. It is fully not understood whether the dysfunction of the 
endothelium  in  the cardiac circulation is a local or a systemic disorder of the 
vascular bed  that happens concurrently in other areas of the circulation. 
Assessing FMD in the  epicardial vessels  is a to a great extent more invasive 
method as  compared with FMD assessment  in the brachial vessels. Hence , 
numerous studies stress on  the issue that assessing FMD in brachial artery 
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could signify as a marker   for analytical evaluation of cardiac  circulation in 
subjects  with apparent coronary artery disease (CAD) or those patients who are  
at danger for  developing  CAD. In these studies conducted  the endothelium-
dependent vasodilatationaswellasthe endothelium- independent vasodilatation in 
the brachial  circulation was observed  in subjects with CAD .  Some studies 
have demonstrated  a  intriguing  association of endothelium function in  
coronary and peripheral vascular bed . It has been revealed that large proportion  
of  subjects  with acute coronary syndromes  had concomitant endothelium 
dysfunction of the brachial vessels in the USG scan. However , this endothelial 
function impairment  was correctable  after management of ACS . Nevertheless, 
the specificity and sensitivity of FMD of brachial artery to foretell relation 
between endothelial dysfunction   CAD  is  questionable as the  subject sample 
involved in the study  so far are too less  to confirm it  as statistically 
significant. In patients with high cholesterol levels ,  systemic hypertension  and 
diabetes mellitus  all of which   regarded  as main cardiovascular riskfactors 
FMD measurement accurately senses endothelium dysfunction in them and 
there is adequate evidence for this. 
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FMD of  the brachial artery is altered more by increased  total cholesterol values 
, as  triglycerides levels  do  not alter it  and total cholesterol levels correlates 
with   extent of endothelial dysfunction .Distortedbioactivityof  nitric oxide 
causes dysfunction of  endothelium  of coronary and peripheral  vessels  in 
patients with arterial hypertension. Rigorousness and extent of arterial 
hypertension as reflected  by the extent of left ventricle  hypertensioninfluences  
the amount of endothelial dysfunction in coronary arteries.  Diabetes also causes 
endothelial dysfunction in the coronary and peripheral vessels. Endothelium-
dependent vasodilatation is impaired in conduit  and resistance vessels of 
patients having  diabetes mellitus .  FMD in humans is very useful not only  to 
measure the extent  of dysfunction in endothelium  in relation to the 
dyslipidemia,  systemic hypertension, and diabetes mellitus   but also useful to 
make reliable diagnosis of endothelial dysfunction in association with 
cardiovascular risk factors .  
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CLINICAL IMPLICATIONS OF ENDOTHELIAL DYSFUNCTION IN 
POPULATIONS AND IN THE INDIVIDUAL 
 
In the coronary arteries, impairment of endothelial function occurs early in the 
course of atherosclerosis in relation to systemic risk factors and abnormal 
hemodynamic shear stresses. The more systemic cardiovascular risk factors are 
present, the worse epicardial vascular function is. Extensive literature 
documents that endothelial dysfunction is associated with almost every 
condition predisposing to atherosclerosis and cardiovascular disease. There are 
many studies correlating endothelial dysfunction (conduit artery and 
microvasculature likewise) with cardiovascular risk. For example, endothelial 
dysfunction has been observed in patients with arterial 
hypertension, normotensive subjects with a family history of 
hypertension, smokers,passive smokers,patients with dyslipidemia, ageing 
patients, those with diabetes mellitus, obese individualpatients with 
hyperhomocysteinemia,individuals with low intracellular magnesium level and 
patients with inflammatory or infectious diseases. Importantly, the effects of 
cardiovascular risk on the endothelium can be seen in children as early as 8 
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years of age. Thus, endothelial dysfunction may represent the effect of these 
risk factors on vascular health. 
The fact that endothelial dysfunction is a systemic condition may explain why 
peripheral endothelial function (microvascular and macrovascular) correlates 
with endothelial function in the coronary arteries. The path physiology behind 
the functional changes in impaired endothelial function also leads to structural 
changes of the vessel over time. In a cross-sectional study in healthy middle-
aged men, there is no evident correlation between brachial FMD and the carotid 
intima-media thickness (IMT); however, in a similar population free of 
cardiovascular disease, FMD correlated with IMT progression over a 6-year 
follow-up. Interestingly, in this study, in contrast to FMD, Framingham risk was 
not correlated with IMT progression. Similarly, FMD also predicted IMT 
progression in less healthy patients as demonstrated after 1 year in hypertensive, 
postmenopausal women. 
Taken together, there is good evidence that endothelial dysfunction is 
significantly associated with the burden of cardiovascular risk and can be 
considered a barometer of the total risk burden (the risk of the risk factors). 
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However, transient endothelial function impairment, example, by intercurrent 
acute illnesses, after strenuous exercise, or with certain foods, has to be taken 
into account, posing a potential limitation for interpretation. Thus, it may be that 
endothelial function measurements should not rely on a single test but rather on 
the average of several tests. 
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Technique of FMD 
 
 
How to prepare the subjects for the study 
 
 
Various modalities  affect FMD response  which includes food, body 
temperature, medication  and  other sympathetic stimuli . Hence, patients  
should be made to  fast for at least eight  to twelve  hours  before the start of 
study, and it  should be performed  in a silentroom and at room temperature . 
Any drugs affecting  vasodilator response   must  be stopped  for at least 1 day 
before study , must avoid  exercise, no consumption of  caffeine containing diet 
, fatty food, smoking etc  . All of these perplexing factors should  be well 
thought-outwhile getting  a patient ready for the study  to deter any of these 
factors intervening with the study. While performing  observational 
cohortstudies, information  must be recorded based on those factors  which can 
influence  the measurement of FMD and subsequently  must attend to its impact 
. 
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EQUIPMENT.  
USG  machines  should  be provided  with  software for 2D imaging, spectral  
and colour  Doppler  system, an internal monitor to record ECG  and avascular 
transducer with high-frequency.  To attain images with adequate resolution for 
successiveexamination needs a linear range transducer with a seven MHZ 
frequency , connected to a high- performance USG  system  . The quality of 
images can be greatly improved with  a system that has numerous linear range  
transducers that can pick up a wide range of frequency ranging from seven to 
twelve MHZ.  Every image frame is timed with correlation  to the events of  
cardiac cycle  and is observed  with concurrent Electrocardiograph video 
recording on the USG scan system. 
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IMAGE ATTAINMENT 
The patient must be  placed in a  supine  position with the forearm in a 
relaxingarrangement forbrachial artery imaging  .The antecubitalfossa is 
focussed  in a longitudinal plane  to image the brachial artery.  For constant 2D  
imaging a section with patent anterior and posterior interfaces between the 
vessel wall and lumen is chosen   . To find out the  maximum  area of the lumen 
, brachial artery cross- sectional images should not be used because of 
insufficient imaging of the lateral walls and there is a problem of skew artefacts 
in this view which  alter the accuracy of  diameter determination.  Both M mode 
and A mode  scan could  be used to assess the diametercontinuously   and yet 
these techniques may be issue to error due to drift in tracking. However there is 
no direct comparison  between  diametermeasurements from  recording using 
wall tracking versus  grayscale images.Anatomical  landmarks such as veins and 
fascias planes should be  noted at the time of image capture to ensure the 
identical image of the artery is captured right through the study. 
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ENDOTHELIUM-DEPENDENTFMD.  
In order togeneratea flowmediated stimuli in the brachial artery, blood pressure 
cuff is initially positioned  preferably  on the forearm. A baseline resting 
brachial artery  image is obtained , and  flow of blood  is also calculated using  
the  velocity signal got  from a midartery sample volumeby time-averaging the 
pulsed Doppler.  Cuff inflation to at least 50 mmhg above systolic pressure to 
cause occlusion of the arterial inflow for at least 5 minutes of standard  time  is 
required . arterial occlusion is created by cuff inﬂation to suprasystolic pressure.  
As a result there is  ischemia and subsequent vasodilation of downstream 
resistance vascular bed through various  auto-regulatory mechanisms already 
described . Immediately following deflation of the  cuff  causes  a short-lived 
high-flow state through the brachial vessel to put up for the dilated downstream 
resistancevessels.The net resultant accumulation of  stress forces   leads to 
brachial artery dilation .  
After cuff deflation the longitudinal  section  of the artery  is imaged and 
recorded constantly from thirty seconds  before to two minutes . Experts have 
widely  used both  cuff occlusion of  upper arm or forearm techniques  , and 
there is no great detail to support  as to which method  gives us the best  results. 
FMD generally induces  a greater % alteration in diameter  when we place the 
cuff on the upper part of arm compared with that induced  by positioning  of the 
cuff on the forearm . Conscription of more number  of resistance vessels or may 
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be due  to direct effects of ischemia on the brachial vessel causes this greater 
amount of flow stimulus.However ,precise data attainment is very challenging 
in this technique  as the image is misshapen by brachial artery collapse  and  
soft tissue alteration .  As theperiod ofcuffinflation increasesfromthirty seconds 
tofive minutes , proportional increase  in brachial  artery diameter also happens. 
No change is noted  after five  and ten  minutes of occlusion; hence , the more 
comfortably  tolerated five  minute  occlusion is generally  used. Other site for 
FMD measurement include  the radial, axillaries and superficial femoral 
arteries. Importantly arteries less than2.5mmindiameteraredifficult to 
measureand vasodilatation is very hard to perceive in arteries  bigger  than five 
mm in diameter.  
 
ANALYSIS  
Eminence of ultrasound images greatly influences the precise analysis of 
brachial artery reactivity .Longitudinal images in which the lumen-intima 
interface is visualized on the near (anterior) and far (posterior) walls  is the ideal 
way to measure the diameter of the brachial artery. When the angle of 
insonation is perpendicularly placed the boundaries are best visualised.  For 
theimagingplane to bisect the artery wall  in the longitudinal direction it needs 
perfect revelation of both the near and far wall lumen tunica intima  boundaries, 
and diameters calculated from these images mostly give away the true diameter. 
The boundaries for  measurements  of brachial artery diameter is made 
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automatically using edge- detection software , once the image for analysis is 
chosen. The  diameter measurement  variability is  most minimal when there is 
an average obtained from a sum of multiple  measurements of diameter  taken 
along the vessel segment and maximum when there is a single measured value.  
When a single point in the length of vessel  is utilised  to find out the maximum  
diameter , cross-sectional images  are not  dependable . The alignment of the 
image decides the measurements of vessel diameter along the longitudinal plane  
. When the plane of the ultrasound beam is not completely bisecting the artery 
skewing occurs.  
TIMING OF FMD 
The relaxationof a stream artery when exposed to amplifiedstress forces causes 
flow mediated vasodilatation which in turn is a endothelium-dependant process.  
During postocclusive reactive hyperaemia there is an large amount of stress 
forces and flow through the artery. Maximumraise in diameter occurs around 
sixty seconds  after release of the cuff occlusion or forty-five  to sixty seconds  
after peak reactive hyperaemic  blood flow and this has been recommended by 
many studies  Period to maximum reactivity ,  vasodilator response  time 
duration and the region under the dilation curve  are the various other modalities 
predicting vasodilator response .  Effectively  using  automated 
electrocardiograph  gating during image attainment  imaging of the brachial 
artery should be calculated at the same time in cardiac cycle .  End diastole is 
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denoted by the onset of R-wave, and end systole is denoted by  the peak of  T-
wave . Peak systolic diameter is largerthanendsystolicdiameter,As theartery 
expands  more during systole to have room for the rise  in  both volume and 
pressure generated by left ventricular contraction.  Various factors like  old age , 
systemic hypertensionand T2DM  significantly alter the vessel compliance  and 
in turn affect the magnitude of systolic expansion of vessel. Hence if the 
measurementof vessel diameter isdone at the  end systole; functional properties 
of the brachial artery may complicate the measurements,however this has not 
been proved in a meticulous trial.  
CHARACTERIZING FMD 
FMD  is classically expressed as a alteration in post-occlusive diameter as a 
percentage from the baseline diameter . This percentage change is influenced by 
the  Baseline diameter  in two ways. First, for any specified absolute change in 
the post occlusive  stimulus diameter, a larger baseline diameter gives a smaller 
amount  of  change in percentage. In order to reduce this error calculating the  
absolute change in diameter is the best method . Second, larger arteries seem to 
dilate relativelyless thanthe smaller arteries . Percentchange seems to be the best 
method  to use if baseline diameter stays constant over time for studies  which 
involve comparisons in the same individual before and after an intervention. 
  
 39 
 
IS THERE ANY ROLE OF ENDOTHELIAL FUNCTION FOR 
PROGNOSIS IN PATIENTS WITH ALREADY ESTABLISHED 
CORONARY ARTERY DISEASE OR EVENTS? 
 
Because endothelial dysfunction plays an important role in the pathogenesis of 
atherothrombotic disease, it is not surprising that many studies have 
demonstrated a potential prognostic role of endothelial function in the coronary 
and peripheral circulation in secondary prevention. First evidence came from 
patients with nonobstructive coronary artery disease in whom significantly 
higher incidences of cardiovascular and cerebrovascular events in those with 
impaired coronary vascular function were found. Similarly, peripheral 
endothelial dysfunction assessed with FMDand venous occlusion 
plethysmography predicted cardiovascular events in patients with coronary 
artery disease and in patients after acute coronary syndromes. In the setting of 
established coronary artery disease, patients with endothelial dysfunction have 
higher rates of adverse cardiovascular events compared with those with normal 
endothelial function, and impaired FMD has been shown to be an independent 
predictor of in-stent stenosis after single-vessel coronary interventions.In 
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patients with advanced ischemic heart failure, endothelial function is a strong 
and independent predictor of 1-year mortality, and in patients with graft 
vasculopathy (atherosclerosis associated with cardiac transplantation), normal 
endothelial function is associated with lower progression of coronary intimal 
thickening; epicardial endothelial dysfunction independently predicts outcome 
in these patients. 
In acute myocardial infarction, microvascular endothelial dysfunction has 
especially been documented to be indicative of a poorer prognosis. For 
example, no reflow on angiography strongly predicts 5-year mortality 
independently of infarct size in patients with acute ST-segment–elevation 
myocardial infarction. Interestingly, no reflow might be reversible in some 
cases, which is associated with a better prognosis. 
ENDOTHELIAL FUNCTION AS A CONTRIBUTOR TO DISEASE 
PROGRESSION? 
Endothelial dysfunction in the periphery and in the coronary arteries is not only 
a marker for cardiovascular risk but also a contributor to the progression of 
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atherosclerosisand cardiovascular events. Interestingly, the atherosclerotic 
epicardial segments that show the most endothelial dysfunction are those with 
characteristics of vulnerable atherosclerotic plaques. These segments are 
characterized by the loss of NO activity and increase in endothelin-1 activity,the 
same segments more likely to progress to obstructive coronary artery disease. 
Importantly, microvascular dysfunction may contribute to the impaired 
regulation of myocardial perfusion by reducing the capacity to increase 
perfusion in response to exercise or mental stress, a circumstance that may lead 
to myocardial ischemia. In the context of myocardial infarction, endothelial 
microvascular dysfunction is an important mediator of the event rather than just 
a consequence, likely via reducing coronary blood flow by altering shear stress 
on the epicardial level, lowering endothelial function, and aggravating thrombus 
formation. Diabetes mellitus and the accumulation of risk factors in the 
metabolic syndrome, for example, have significant deleterious effects on 
myocardial perfusion and infarct size in patients with an acute 
infarction.Moreover, patients with preprocedural impairment of microvascular 
function are more likely to have postprocedural microvascular impairment, 
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procedure-related injury, and a worse outcome.Thus, preexisting microvascular 
endothelial dysfunction leads to a greater vulnerability to myocardial injury, 
highlighting the potentially clinically relevant role of a dysfunctional 
microcirculation and damage. 
DOES ENDOTHELIAL FUNCTION IDENTIFY RESPONDERS AND 
NON RESPONDERS TO THERAPY? 
Many medical or lifestyle interventions can improve endothelial function and 
reduce cardiovascular events. For example, Statin treatment significantly 
improves peripheral and coronary vascular function, although not all studies 
were able to prove such an effect within a 6-month treatment period. Of note, 
the impact on risk reduction despite this successful intervention is limited and is 
in the range of ≈20% to 45% in clinical trials. Even with the combination of all 
therapies proven to lower risk in secondary prevention (or primary prevention), 
some patients may develop later events and therefore are obviously not 
completely protected by their therapy. 
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Therefore, it is the ultimate goal to identify those patients who will develop 
future events despite therapy (to potentially escalate and intensify current 
treatment). One concept could be to measure the individual impact of therapy 
on endothelial function as a parameter of cardiovascular disease, targeting 
those with no improvement in vascular function. Important studies in this 
respect have recently been performed. 
 
IS IMPROVEMENT IN ENDOTHELIAL FUNCTION AN INDICATOR 
OF SUCCESSFUL TREATMENT? 
It is probably a good sign when endothelial dysfunction is (partly) reversed with 
treatments. The first proof of this principle came from 2 controlled studies in 
1995 in which cholesterol-lowering therapy (statins) improved endothelial 
function. Statins now have convincing evidence for their beneficial effect on 
coronary and peripheral endothelial function, likely because of their 
antiinflammatory and antioxidant properties and because of the restoration of 
the vascular NO bioavailability. Since the first evidence in humans with statins, 
numerous interventions in a broad range of patients have demonstrated a 
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beneficial effect on endothelial function. Most pharmacological intervention 
studies with an effect on cardiovascular risk factors also show improved 
endothelial function. For example, antihypertensive therapy in generalsuch as 
angiotensin-converting enzyme inhibitors, angiotensin receptor 
blockers, calcium channel blockers, and certain β-blockers, particular the NO 
group containing the molecule nebivolol, might reverse endothelial dysfunction; 
however, angiotensin-converting enzyme inhibitors seem to be particularly 
important. Calcium channel blockers reduce calcium entry though L-type 
voltage-dependent channels of the vascular muscle cells, thus dilating coronary 
and other arteries. Additionally, some calcium channel blockers activate 
endothelial NO synthase or have antioxidative properties, thus increasing NO 
bioavailability. The Evaluation of Nifedipine and Cerivastatin on Recovery of 
Coronary Endothelial Function-1 and -2 (ENCORE-1 and -2) trials showed that 
long-acting nifedipine consistently improved coronary endothelial function in 
patients with stable coronary artery disease and that the improvement persisted 
even after cessation of the drug. Angiotensin-converting enzyme inhibitors and 
angiotensin receptor blockers are also preferred medications in diabetes 
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mellitus. Diabetes-modulating drugs like metformin or glitazones may also 
improve vascular function in patients with type 2 diabetes mellitus; however, 
the latter may have negative effects on cardiovascular risk, thus limiting its use. 
Not only pharmacological agents but also lifestyle factors and medications that 
increase the release of or prevent the degradation of endothelium-derived 
relaxing factors, NO in particular, and those that decrease the production of 
endothelium-derived constricting factors such as endothelin, among others, can 
improve endothelial function. Many interventions such as physical 
exercise, weight reduction (including bariatric surgery),and enhanced external 
counterpulsation and dietary interventions with foods rich in polyphenols, 
especially fruits, tea, and cocoa, have been demonstrated to be beneficial for 
microvascular or macrovascular endothelial function by increasing NO 
bioavailability. An important lifestyle modification with an impact on 
endothelial function is smoking cessation. Smoking cessation clearly 
demonstrates a favourable effect on epicardial coronary endothelial 
function that was not observed in the microvasculature. This finding 
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demonstrates the differences in macrovascular function and microvasculature 
function and their complex, incompletely understood interactions. 
Although therapies with a proven benefit on morbidity and mortality in 
cardiovascular patients concordantly improve endothelial function, it is not 
certain whether the opposite is always true. For example, vitamin C or E and 
folic acid supplementation, praised for their antioxidative capacity and 
associated with significant acute improvement in endothelial function, failed to 
show any benefit in the long term or in cardiovascular disease prevention so far. 
On the other end, the path physiological information derived from studies on 
endothelial function is not correctly applied in clinical trials. Available evidence 
demonstrates that vitamin C can improve endothelial function but also that this 
effect is obtained with concentrations much higher than those reached after oral 
administration. Many studies evaluating path physiological aspects were 
performed in the setting of acute intravenous or intraatrial interventions. 
Moreover, the response to vitamins may be dependent on the presence of 
increased endogenous oxidative stress. This kind of information should be 
evaluated carefully during the design of intervention studies. The abundant 
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current trials with any kind of positive effects on the endothelium are path 
physiologically interesting, but care should be taken to extrapolate the findings 
to cardiovascular morbidity and mortality. Finally, it is of concern that the drug 
effects on endothelial function may be different according to which vascular 
bed is considered. Additionally, many lifestyle interventions, foods, and drugs 
have been shown to improve endothelial dysfunction in a population as a whole, 
but not necessarily in the individual patient, a fact which should be addressed in 
further studies. 
ARE MICROVASCULAR FUNCTION AND CONDUIT VESSEL 
ENDOTHELIAL FUNCTION COMPARABLE? 
Although cardiovascular risk factors are associated with endothelial dysfunction 
in virtually every arterial bed, because of the different physiological role of 
conduit and resistance arteries, important differences should be considered. 
Whereas reduced NO release in response to stimuli plays a central role in the 
pathophysiology of endothelial dysfunction in the conduit arteries, NO in the 
microcirculation may primarily modulate tissue metabolism. Furthermore, 
metabolic and other factors are becoming increasingly important in the 
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regulation of microvascular function. Therefore, pharmacological tests inducing 
NO release might not reflect the physiological adaption of endothelial function 
in the microvasculature in response to exercise or ischemia. 
The aforementioned differential effect of smoking on microvasculature and 
epicardial vasculature as outlined above might be only 1 example.Furthermore, 
FMD is particularly sensitive to being impaired by traditional risk factors (eg, 
age, hypertension), whereas the peripheral arterial tonometry reactive 
hyperaemia index (microvasculature) is more sensitive to metabolic risk factors, 
especially body mass index and diabetes mellitus(and interestingly shows a 
paradoxical association with age in the Framingham cohort). Microvascular and 
macrovascular dysfunction could also reflect different stages of vascular disease 
in that conduit artery endothelial dysfunction may be more important in patients 
with existing atherosclerosis and microvascular dysfunction may be an earlier 
indicator of risk. The fact that microvascular endothelial function and 
macrovascular endothelial function only show a weak (if any) correlation with 
each othershould caution against the extrapolation of findings in 1 circulation 
level to the other. 
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Given that macrovascular and microvascular endothelium is susceptible to 
different risk factors, both should be evaluated whenever possible. 
IS THERE A ROLE OF ENDOTHELIAL FUNCTION IN DRUG-
DEVELOPMENT PROGRAMS? 
For new drugs, the requirement by drug regulation authorities is to prove the 
principle by primum non nocere (first, do no harm); however, testing the effect 
of a certain drug on morbidity and mortality requires large sample sizes. 
Sometimes, such as for drugs with relatively small effects on the cardiovascular 
system or in children, such outcome trials are not feasible at all. Clinical 
endothelial function evaluation is of potential value in reassessing the risk of 
drug-development programs, especially as it becomes more challenging to 
choose novel agents for clinical use. With endothelial function as a mechanistic 
surrogate integrating various types of cardiovascular risks, the sample size can 
be significantly smaller compared with clinical end-point trials. Furthermore, 
endothelial function may respond rapidly to therapies (within hours, days, or 
weeks), long before the effects on clinical outcomes are seen. Thus, the impact 
on endothelial function may give important signals of efficacy or, more 
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important, may warn of potential harm. Therefore, endothelial function not only 
is a valuable measure to assess drug efficacy on surrogate end points but also 
may play an important potential role in the evaluation of drug safety, as 
exemplified in the recently completed Dalcetrapib's effects on vascular function 
study (DAL-VESSEL) study, notably the first multicenter study to use FMD as 
outcome measure. For certain studies, a multimodality approach, which includes 
peripheral endothelial function measurements, may be of particular value. 
 
WHAT KIND OF STUDIES DO WE NEED IN THE FUTURE? 
As outlined above, endothelial function measurement may differentiate 
responders from nonresponders to therapy. In secondary prevention, studies 
demonstrate that patients who do not respond to interventions with improved 
endothelial function are at a considerable risk for further events. These early 
data suggest that therapy guided by individual endothelial function 
measurements might be feasible in these settings, but larger studies in this 
respect are needed to answer the question of whether endothelial function–
guided therapies help to improve outcomes. 
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In primary prevention, it is still unknown whether endothelial function should 
be assessed in apparently healthy individuals at low risk from traditional risk 
factors. To address this issue, endothelial dysfunction, which depicts 
mechanisms at the core of atherosclerosis and its complications, could be 
chosen for future similar studies, with different medical and lifestyle 
interventions to be tested. Designing such a trial would require very careful 
consideration of which noninvasive test or combination of tests of endothelial 
function should be included. If such results prove positive, there would be a 
good rationale to implement endothelial function testing in everyday clinical 
practice. 
Currently, clinical guidelines and risk management for prevention are based on 
the risk factors established in the Framingham study and certain cardiovascular 
surrogates such as carotid IMT and coronary calcium. However, the 
Framingham score and other scores provide inconsistent results when applied to 
different populations, and adjustment based on different populations might be 
needed. Additionally, the Framingham score is limited to the fact that risk 
factors were collected years ago, when, for example, no statin therapy was 
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available and most people smoked or were exposed to secondhand smoke. The 
effect of a changing environment might be better depicted by endothelial 
function assessments. With the assumption that endothelial function provides an 
integrated functional risk assessment, the question of whether endothelial 
function might be a better predictor for cardiovascular events than the actual 
scoring systems is intriguing and should be tested with larger-scale studies. 
When using the Framingham Risk Score, we are aware how to deal with 
patients in the high- or low-risk category. However, many patients end up 
having intermediate risk; for these patients, the recommendation are less clear. 
As demonstrated by the studies discussed above, reclassification of patients 
with intermediate risk according to their endothelial function seems to be 
feasible and reasonable, although further studies in this area are required. 
FMD MEASUREMENTS IN HUMANS: GENETIC AND PROGNOSTIC 
ASPECTS  
To explore the aspects of genetic influence  on early vasculature physiology 
which could  be significant to a afterwards clinical disease reactivity of brachial 
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artery has been used effectively. Brachial artery FMD seems to be influenced by 
intrauterine and childhood factors. Latest studies have illustrated that FMD 
definitely and appreciably  correlates with birth weight. Long-term alterations  
in vascular function which are apparent by the  1st decade of life may be 
associated with growth in-utero and other unidentified growth determinants . As 
a important contributor in the pathogenesis of atherosclerosis in adults 
endothelial dysfunction has been highlighted . FMD is impaired with 
progressive atherosclerosis (14, 71). Furthermore, there is some evidence that a 
Impaired  FMD in coronary arteries predicts cardiovascular incident rates and is 
significantly . Measuring FMD  of brachial artery is a non invasive analytical 
procedureand therefore it permits feasible  evaluation of endothelial function  in 
offspring or in 1ST -degree relatives of subjects  with apparent  atherosclerosis. 
Even if there islack of other risk factors , young healthy adults with a family 
history of early onset CAD have endothelial dysfunction as predicted by an 
impaired FMD. In offspring of patients with premature CAD brachial artery 
FMD impairment coincides and correlates with a increased carotid artery intima 
thickness , demonstrating  a early structural and functional changes of the 
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vascular endothelium  . Even in first-degree relatives of subjects with T2DM 
identical results were observed  . To potentially recognize subjects at risk for 
atherosclerotic complications , measurement of FMD is very useful. FMD is 
useful in prognostic predictions of endothelial dysfunction and also in risk 
stratification of high risk individuals.Even environmental factors could affect 
vascular function. After assessing brachial artery FMD, it has been established 
that passive smoking alters endothelial function in human beings . The 
combined determination of FMD and By using single nucleotide 
polymorphisms of target genes concerned in atherosclerosis and along with it 
combined determination of brachial artery FMD  in studies involving very large 
patient populations could  surely endow with new information and   new 
insights into the pathogenesis of early atherosclerosis. 
FMD MEASUREMENTS IN HUMANS: OUTLOOK AND FUTURE 
PERSPECTIVES  
Numerous  experimental models have been studied extensively to understand 
the underlying physiological mechanism of FMD.  To explore endothelial 
function one of the most commonly used method is by assessing FMD . 
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Alterations in FMD have been documented Inpatients with  major 
cardiovascular risk factorsconsidered .Considering studies in   huge subject 
populations and while comparing  data from various labs , proper 
standardization of FMD measurement is required. In FMD measurement there is 
a absolute need for an international consensus for normal(baseline) , borderline 
and pathological indication values .  For accurate detection of boundaries  of the 
brachial artery wall a latest automated analysis system was developed , which 
khelped indecreasing  variability and study time of FMD measurement .  To 
prove that there is a causal relation between endothelial dysfunction and the 
clinical predictors of cardiovascular morbidity and mortality , FMD 
measurements must be carried out in large scale trials and this definitely 
k8requires  much superior methods of FMD measurement  .  In clinical routine 
FMD serves as a valuable stand-in of endothelial dysfunction and also as a 
biomarker  .  For a better understanding of various phases in the pathogenesis of 
atherosclerosis, new breakthrough in the field of DNA array technologies will 
aid us in recognizing the  target genes responsible  . Categorization of 
differential gene expression will  allow us to  obtain 
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clinicaldiagnosisofvasculardiseases which remain subclinical and this could be 
made more effective along with a combined measurement of FMD and IMT 
.FMD assessment provides a more functional and genomic approach to study 
CAD apart from merely coronary angiographic changes with the perspective  to 
lay down various  new strategies in risk stratification and deciding on goals of 
treatment 
APPLICATION IN CLINICAL TRIALS  
 In view  ease to  use, high efficacy and noninvasive nature assessment of 
brachial artery FMD in clinical trials has drastically improved .  Several factors 
must  be well thought-out while preparation of  a clinical trial in which  FMD is 
the end aim of interest due to the technical and biological variability of the 
measurement that consist of study design, sample size and uniform technique.  
Latest  studies that include both acute and long term intervention trials have 
demonstrated   the outcome of pharmacologic or physiologic interventions on 
brachial artery FMD .  The major proportion of  studies up till now have been 
from single centre institutions, but multicenter trails are also  being undertaken , 
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with both crossover  and parallel-group design being effectively used .In a 
crossover design study minimum of twenty to thirty patients may be required 
for a significant improvement in FMD  and forty to sixty  patients in a parallel-
group design study.  An absolute change in FMD of 1.5 percent to 2 percent 
needs to be observed following a intervention , which could be shown as 
statistically significant improvement in our study.  
FUTURE DIRECTIONS  
 In spite of various  new approaches and indigenous scientific advances  that 
have emerged, USG measurement of brachial artery FMD has provide us the 
most vital and accurate inputs about endothelial function in healthy and 
diseased individuals.To obtain vital data about microvasculature  endothelial 
function spectral Doppler is very useful to reproducibly quantify the changes in 
flow in the brachial artery during FMD procedure . In establishing the clinical 
efficacy of brachial artery FMD there is a huge amount of interest that is 
developing among clinicians. Studies have hypothesized that endothelial 
dysfunction could  prove to be a preclinical indicator of cardiovascular disease 
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burden and also serves as an predictive bridging  index of genetic susceptibility 
and risk factor burden .  Endothelial dysfunction of the coronary arteries is an 
self-determining predictor of cardiovascular disease events and this has been 
well established by various studies.  
 Upcoming several large population trials that includes the Framingham Heart 
Study and the Cardiovascular Health Study, should be able to decide whether 
endothelial dysfunction in the brachial artery will recognize patients at risk for 
developing CAD , CVA and peripheral vascular disease .Forswot upof the 
initial stages of atherosclerosis in children and young adults this technique is 
very helpful , thus giving us adequate chance for prevention and early 
intervention.  As there is an attempt to modify the  risk factors  and early 
intervention  with drugs  well known to decrease cardiovascular risk , 
consequently brachial artery vascular reactivity improves drastically and this 
has been proved by numerous studies . Whether this enhancement in  vascular 
endothelial function directly brings about an overall improved outcome of the 
patient remains questionable. FMD may be used  to assess the response to drug 
therapy and to prioritize individual patient risk factor modification programs in 
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the near future by clinicians. In order to make  FMD a clinically effective tool to  
measure or quantify cardiovascular risk in an individual or involving a large 
group ,further supportive studies are required to decide whether this technique is 
constantly reproducible and whether there is sufficiently low bio variability 
amongst subjects . To that day, thistechnique will need time  to mature, with 
officialtraining opportunities for , certification and continuing medical 
education, as currently exist for other cardiovascular testing modalities 
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AIMS AND OBJECTIVES 
 
 
PRIMARY OBJECTIVE 
 
TO STUDY THE CORRELATION  BETWEEN FLOW 
MEDIATED VASODILATATION OF BRACHIAL ARTERY  AND 
CORONARY ANGIOGRAPHIC CHANGES 
 
SECONDARY OBJECTIVES 
 
1. TO ASSESS THE CORRELATION BETWEEN  OTHER 
WELL ESTABLISHED CARDIOVASCULAR RISK FACTORS 
LIKE SMOKING, WAIST HIP RATIO, LIPID ABNORMALITIES 
AND CAROTID INTIMA MEDIA THICKNESS. 
 
2. TO ASSESS THE RELATIONSHIP BETWEEN PER-CAPITA 
INCOME AND CAG CHANGES 
 
3. TO ASSESS THE RELATIONSHIP BETWEEN DIET 
PREFERRENCE AND CAG CHANGES 
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MATERIALS AND METHODS 
 
 
 
PLACE OF STUDY: 
 
 DEPARTMENT OF CARDIOLOGY, CARDIOLOGY OPD, MEDICAL 
WARDS AND IMCU AT STANLEY MEDICAL COLLEGE AND 
HOSPITAL, CHENNAI. 
DURATION:JAN 2014 TO SEP 2014. 
 
STUDY DESIGN:RETROSPECTIVE OBSERVATIONAL STUDY 
 
SAMPLE SIZE: 75 
 
 
METHODOLOGY- 
Patients diagnosed with coronary artery disease within 1 month 
and have undergone coronary angiogram ;from the period 
January 2014 to September 2014 in ICCU/ cardiology wards are 
included in the study. Patients will be subjected to symptom 
analysis, clinical examination, laboratory investigations and 
flow mediated vasodilation studies of brachial artery. The final 
analysis will be made at the end of the study to achieve the fore 
mentioned goals using appropriate statistical methods. 
 62 
 
PATIENT SELECTION: 
 
INCLUSION CRITERIA 
 
1. All patients who have been diagnosed having coronary 
artery disease which includes chronic stable angina, ST 
elevation MI, non ST elevation MI , unstable angina 
within the last 1month and have undergone CAG. 
 
2. All patients who have undergone primary/ facilitated PCI 
within the above mentioned time. 
 
3. Patients between 20 and 60 years of age. 
 
EXCLUSION CRITERIA 
 
1. Patients with any form of connective tissue disorder, 
chronic kidney disease, Chronic liver disease 
 
2. Any patient < 20 and > 60 yrs of age. 
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Study Groups 
Treatment Groups Name of Group Number of Subjects 
Group A Non Critical CAD 18 
Group B SVD 33 
Group C DVD 8 
Group D TVD 16 
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Statistics  
 
Descriptive statistics was done for all data and suitable statistical tests of 
comparison were done. Continuous variables were analysed with ANOVA and 
categorical variables were analysed with the Chi-Square Test and Fisher Exact 
Test. Statistical significance was taken as P < 0.05. The data was analysed using 
Epi Info software (7.1.0.6 version; Centre for disease control, USA) and 
Microsoft Excel 2010. 
 
SAMPLE SIZE CALCULATION 
Sample size was determined on the basis of a pilot study in which the presence 
increased percentage of FMD was measured at 4%.  We calculated a minimum 
sample size of 59 patients was required, assuming a type 1 error (two-tailed) of 
0.05 and a margin of error of 10%. Therefore, the final sample selected was 
n=75. 
 
n= t² x p(1-p) 
  m² 
Description: 
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n = required sample size 
t = confidence level at 95% (standard value of 1.96) 
p = estimated prevalence of malnutrition in the project area 
m = margin of error at 10% (standard value of 0.05) 
 
n= 
(1.96)² x 0.04(1-
0.96) 
             (0.05)² 
 
n= 3.8146 x 0.0384 
  
           0.0025 
 
= 59  
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Age  
 
 
AGE DISTRIBUTION 
Non Critical 
CAD 
SVD DVD TVD 
N 18 33 8 16 
MEAN 53.11 47.85 50.88 54.69 
SD 5.87 7.72 10.87 4.63 
 
AGE 
DISTRIBUTION 
Non 
Critica
l CAD 
% SVD % DVD % TVD % 
≤ 20 years 0 0 0 0 0 0 0 0 
21 to 40 years 1 6 9 27 2 25 0 0 
41 to 60 years 17 94 24 73 6 75 15 94 
> 60 years 0 0 0 0 0 0 1 6 
Total 18 100 33 100 8 100 16 100 
P value 
ANOVA 
0.1376 
By conventional criteria the association between the study groups and 
age is considered to be not statistically significant since p > 0.05 
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Gender  
 
 
 
GENDER 
DISTRIBUTIO
N 
Non 
Critical 
CAD 
% SVD % DVD % TVD % 
Male 9 50.00 21 63.64 6 75.00 15 93.75 
Female 9 50.00 12 36.36 2 25.00 1 6.25 
Total 18 100 33 100 8 100 16 100 
chi-square statistic 9.06  
degrees of freedom 3 
P value 
Chi Squared Test 
0.6000 
 
By conventional criteria the association between the study groups and gender is considered to 
be not statistically significant since p > 0.05. 
 
Since age and gender is not statistically significant, it means that there is no difference 
between the groups. In other words the groups contain subjects with the same basic 
demographic characteristics.  
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Smoking  
 
 
SMOKIN
G 
Non 
Critical 
CAD 
% SVD % DVD % TVD % 
Smoking 
- 
14 77.78 18 54.55 2 25.00 2 12.50 
Smoking 
+ 
4 22.22 15 45.45 6 75.00 14 87.50 
Total 18 100 33 100 8 100 16 100 
chi-square statistic 6.89 
degrees of 
freedom 
3 
P value 
Chi Squared Test 
0.142 
 
 
By conventional criteria the association between the study groups and smoking 
is considered to be not statistically significant since p > 0.05. 
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Smoking Duration 
 
 
SMOKING 
DURATION 
Non Critical CAD SVD DVD TVD 
N 3 13 6 8 
MEAN 2.00 3.85 4.33 23.50 
SD 0.00 3.69 5.43 10.41 
 
SMOKING 
DURATION 
Non 
Critical 
CAD 
% SVD % DVD % TVD % 
≤ 5 years 3 100 5 38 0 0 1 13 
6 to 10 
years 
0 0 8 62 1 17 0 0 
11 to 15 
years 
0 0 0 0 4 67 1 13 
> 15 years 0 0 0 0 1 17 6 75 
Total 3 100 13 100 6 100 8 100 
P value 
ANOVA 
0.0000043 
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By conventional criteria the association between the study groups and duration 
of smoking levels among study subjects is considered to be statistically 
significant since p < 0.05.  
 
 
 
 
Statistical Significance 
 
This indicates that there is a true difference among groups and the difference is 
significant. . In simple terms, when studying the association between flow 
mediated vasodilatation and coronary  angiographic changes, the duration of 
smoking in non-critical CAD group is predominantly less(2 years) when 
compared to SVD group(3.85 years), DVD group(4.33) and TVD group(23.50 
years). It is statistically significant with a p-value of 0.0000 according to 
ANOVA. 
 
Clinical Significance 
 
The average duration of smoking in non-critical CAD group is meaningfully 
less than SVD group by 1.92 times with a mean difference of 1.85 years. 
 
The average duration of smoking in non-critical CAD group is meaningfully 
less than DVD group by 2.16 times with a mean difference of 2.33 years. 
 
The average duration of smoking in non-critical CAD group is meaningfully 
less than TVD group by 11.75 times with a mean difference of 21.50 years. 
 
This difference is true and significant and has not occurred by chance. 
 
Conclusion  
We conclude that there is meaningfully real increase in severity of CAD as 
duration of smoking increases in our study subjects.  
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Alcoholism  
 
 
ALCOHOLISM 
Non Critical 
CAD 
SVD DVD TVD 
N 18 33 8 16 
MEAN 0.06 0.30 0.13 0.00 
SD 0.24 0.47 0.35 0.00 
 
 
ALCOHOLIS
M 
Non 
Critica
l CAD 
% SVD % DVD % TVD % 
Alcoholism - 17 94 23 70 7 88 16 100 
Alcoholism + 1 6 10 30 1 13 0 0 
Total 18 100 33 100 8 100 16 100 
chi-square statistic 10.1  
degrees of freedom 3 
P value 
Chi Squared Test 
0.308 
By conventional criteria the association between the study groups and 
alcoholism is considered to be not statistically significant since p > 0.05. 
17
1
23
10
7
1
16
0
0
5
10
15
20
25
Alcoholism - Alcoholism +
N
u
m
b
e
r 
o
f 
Su
b
je
ct
s
ALCOHOLISM
Non Critical CAD SVD DVD TVD
72 
 
Alcoholism Duration 
 
 
 
 
ALCOHOLISM 
DURATION 
Non Critical CAD SVD DVD TVD 
N 1 9 1 0 
MEAN 5.00 4.67 5.00 0 
SD 0 6.18 0 0 
 
ALCOHOLIS
M 
DURATION 
Non 
Critical 
CAD 
% SVD % DVD % TVD % 
≤ 5 years 1 100 7 78 1 100 0 0 
6 to 10 years 0 0 0 0 0 0 0 0 
11 to 15 
years 
0 0 2 22 0 0 0 0 
> 15 years 0 0 0 0 0 0 0 0 
Total 1 100 9 100 1 100 0 0 
P value 
ANOVA 
0.999997886 
 
By conventional criteria the association between the study groups and duration 
of alcohol intake is considered to be not statistically significant since p > 0.05. 
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Diet  
 
 
 
 
 
TYPE OF 
DIET 
Non 
Critical 
CAD 
% SVD % DVD % TVD % 
Vegetarian 4 22 6 18 0 0 0 0 
Non-
Vegetarian 
14 78 27 82 8 100 16 100 
Total 18 100 33 100 8 100 16 100 
chi-square statistic 5.69  
degrees of freedom 3 
P value 
Chi Squared Test 
0.223 
 
By conventional criteria the association between the study groups and type of 
diet intake is considered to be not statistically significant since p > 0.05.  
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Hypertension  
 
 
 
HYPERTENSIO
N 
Non 
Critical 
CAD 
% SVD % DVD % TVD % 
Normal 7 39 23 70 6 75 11 69 
Hypertensive 11 61 10 30 2 25 5 31 
Total 18 100 33 100 8 100 16 100 
chi-square statistic 9.25  
degrees of freedom 3 
P value 
Chi Squared Test 
0.055 
 
 
By conventional criteria the association between the study groups and 
hypertension status is considered to be not statistically significant since p > 
0.05. 
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Duration of Hypertension 
 
 
 
DURATION OF 
HYPERTENSION IN 
YEARS 
Non Critical CAD SVD DVD TVD 
N 11 10 2 5 
MEAN 4.45 3.00 10.00 4.40 
SD 3.08 2.30 0.00 1.34 
 
 
DURATION OF 
HYPERTENSION 
IN YEARS 
Non 
Critical 
CAD 
% SVD % DVD % TVD % 
≤ 5 years 8 73 7 70 0 0 5 100 
6 to 10 years 3 27 3 30 2 100 0 0 
11 to 15 years 0 0 0 0 0 0 0 0 
> 15 years 0 0 0 0 0 0 0 0 
Total 11 100 10 100 2 100 5 100 
P value 
ANOVA 
0.111981261 
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By conventional criteria the association between the study groups and duration of 
hypertension is considered to be not statistically significant since p > 0.05. 
Diabetes 
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By conventional criteria the association between the study groups and diabetes 
status levels among study subjects is considered to be statistically significant 
since p < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
DIABETES 
Non 
Critical 
CAD 
% SVD % DVD % TVD % 
Normal 10 56 15 45 3 38 4 25 
Diabetic 8 44 18 55 5 63 12 75 
Total 18 100 33 100 8 100 16 100 
chi-square statistic 14.5 
degrees of freedom 3 
P value 0.006 
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Statistical Significance 
 
This indicates that there is a true difference among groups and the difference is 
significant. . In simple terms, when studying the association between flow 
mediated vasodilatation and coronary  angiographic changes, the diabetes 
status in non-critical CAD group(44%) is predominantly less when compared to 
SVD(55%), DVD(63%) and TVD(75%) groups. It is statistically significant 
with a p-value of 0.006 according to chi squared test. 
 
 
 
Clinical Significance 
 
The diabetic status in non-critical CAD group is meaningfully less than SVD 
group by 1.22 times with a mean difference of 10 percentage points. 
 
The diabetic status in non-critical CAD group is meaningfully less than DVD 
group by 1.15 times with a mean difference of 8 percentage points. 
The diabetic status in non-critical CAD group is meaningfully less than TVD 
group by 1.2 times with a mean difference of 13 percentage points .This 
difference is true and significant and has not occurred by chance. 
 
Conclusion We conclude that there is meaningfully real increase in severity of 
CAD in relation to diabetic status in our study subjects.   
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By conventional criteria the association between the study groups and duration 
of diabetes among study subjects is considered to be statistically significant 
since p < 0.05.  
 
 
DURATION OF 
DIABETES IN YEARS 
Non Critical CAD SVD DVD TVD 
N 10 8 8 10 
MEAN 2.90 4.25 5.25 7.30 
SD 2.01 2.49 2.25 6.41 
DURATION OF 
DIABETES IN 
YEARS 
Non Critical 
CAD 
% SVD % DVD % TVD % 
≤ 5 years 10 100 7 88 6 75 6 60 
6 to 10 years 0 0 1 13 2 25 2 20 
11 to 15 years 0 0 0 0 0 0 0 0 
> 15 years 0 0 0 0 0 0 2 20 
Total 10 100 8 100 8 100 10 100 
P value 
ANOVA 
0.0111981261 
81 
 
Statistical Significance 
 
This indicates that there is a true difference among groups and the difference is 
significant. . In simple terms, when studying the association between flow 
mediated vasodilatation and coronary  angiographic changes, the duration of 
diabetes in non-critical CAD group is predominantly less(2.9 years) when 
compared to SVD group(4.25years), DVD group(5.25) and TVD group(7.30 
years). It is statistically significant with a p-value of 0.0112 according to 
ANOVA. 
 
Clinical Significance 
 
The average duration of diabetes in non-critical CAD group is meaningfully less 
than SVD group by 1.47 times with a mean difference of 1.35 years. 
 
The average duration of diabetes in non-critical CAD group is meaningfully less 
than DVD group by 1.24 times with a mean difference of 1.00 years. 
 
The average duration of diabetes in non-critical CAD group is meaningfully less 
than TVD group by 1,39 times with a mean difference of 2.05 years. 
 
This difference is true and significant and has not occurred by chance. 
 
Conclusion We conclude that there is meaningfully real increase in severity of 
CAD as duration of diabetes increases in our study subjects.   
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By conventional criteria the association between the study groups and BMI 
among study subjects is considered to be statistically significant since p < 0.05.  
 
 
 
BMI NORMAL 
Non 
Obstructive 
CAD 
SVD DVD TVD 
N 8 18 33 8 16 
MEAN 24.34 27.38 29.15 30.15 31.34 
SD 2.89 3.40 4.64 2.59 1.95 
BMI 
Non 
Critical 
CAD 
% SVD % DVD % TVD % 
Normal 4 22 10 30 4 50 8 50 
Overweight 9 50 16 48 4 50 8 50 
Obese 5 28 7 21 0 0 0 0 
Total 18 100 33 100 8 100 16 100 
P value 
ANOVA 
0.02694 
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Statistical Significance 
 
This indicates that there is a true difference among groups and the difference is 
significant. . In simple terms, when studying the association between flow 
mediated vasodilatation and coronary  angiographic changes, the BMI in non-
critical CAD group is predominantly less(24.34) when compared to non-
obstructive CAD(27.38),  SVD group(29.15), DVD group(30.15) and TVD 
group(31.34). It is statistically significant with a p-value of 0.0112 according to 
ANOVA. 
 
Clinical Significance 
 
The average duration of diabetes in non-critical CAD group is meaningfully less 
than SVD group by 1.20 times with a mean difference of 4.81 points.. 
 
The average duration of diabetes in non-critical CAD group is meaningfully less 
than DVD group by 1,24 times with a mean difference of 5.81 points. 
 
The average duration of diabetes in non-critical CAD group is meaningfully less 
than TVD group by 1,29 times with a mean difference of 7.00 points. 
 
This difference is true and significant and has not occurred by chance. 
 
Conclusion  
We conclude that there is meaningfully real increase in severity of CAD as BMI 
increases in our study subjects.   
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By conventional criteria the association between the study groups and LDL 
levels among study subjects is considered to be statistically significant since p < 
0.05.  
LDL Non Critical CAD SVD DVD TVD 
N 18 33 8 16 
MEAN 93.00 95.63 99.39 103.81 
SD 8.29 10.13 6.43 9.45 
LDL 
Non 
Critical 
CAD 
% SVD % DVD % TVD % 
≤ 90 mm 
mg/dl 
10 56 9 27 2 25 6 38 
91 to 100 
mg/dl 
5 28 6 18 4 50 5 31 
101 to 110 
mg/dl 
3 17 16 48 2 25 5 31 
> 110 
mg/dl 
0 0 2 6 0 0 0 0 
Total 18 100 33 100 8 100 16 100 
P value 
ANOVA 
0.02561195 
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Statistical Significance 
 
This indicates that there is a true difference among groups and the difference is 
significant. . In simple terms, when studying the association between flow 
mediated vasodilatation and coronary  angiographic changes, the LDL levels in 
non-critical CAD group is predominantly less(93.00 mg/dl) when compared 
SVD group(95.63 mg/dl), DVD group(99.39 mg/dl) and TVD group(103.81 
mg/dl). It is statistically significant with a p-value of 0.0256 according to 
ANOVA. 
 
Clinical Significance 
 
The average duration of diabetes in non-critical CAD group is meaningfully less 
than SVD group by 1.02 times with a mean difference of 2.63 mg/dl. 
 
The average duration of diabetes in non-critical CAD group is meaningfully less 
than DVD group by 1,06 times with a mean difference of 6.39 mg/dl. 
 
The average duration of diabetes in non-critical CAD group is meaningfully less 
than TVD group by 1,12 times with a mean difference of 10.81 mg/dl. 
 
This difference is true and significant and has not occurred by chance. 
 
Conclusion We conclude that there is meaningfully real increase in severity of 
CAD as LDL increases in our study subjects.   
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HDL 
 
 
 
HDL Non Critical CAD SVD DVD TVD 
N 18 33 8 16 
MEAN 41.94 41.67 38.50 42.69 
SD 4.71 5.54 7.54 5.84 
 
HDL 
Non 
Critical 
CAD 
% SVD % DVD % TVD % 
≤ 40 mm 
mg/dl 
7 39 15 45 6 75 4 25 
41 to 50 
mg/dl 
10 56 18 55 2 25 12 75 
51 to 60 
mg/dl 
1 6 0 0 0 0 0 0 
> 110 mg/dl 0 0 0 0 0 0 0 0 
Total 18 100 33 100 8 100 16 100 
P value 
ANOVA 
0.554489079 
By conventional criteria the association between the study groups and HDL status is 
considered to be not statistically significant since p > 0.05. 
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By conventional criteria the association between the study groups and LVEF% 
among study subjects is considered to be statistically significant since p < 0.05. 
LVEF(%) Non Critical CAD SVD DVD TVD 
N 16 8 33 10 
MEAN 61.00 56.75 46.45 39.22 
SD 2.73 3.63 2.05 1.46 
LVEF(%) 
Non 
Critical 
CAD 
% SVD % DVD % TVD % 
≤ 40 % 0 0 0 0 0 0 5 50 
41 to 50  
% 
0 0 0 0 29 88 5 50 
51 to 60  
% 
10 63 8 100 4 12 0 0 
> 60  % 6 38 0 0 0 0 0 0 
Total 16 100 8 100 33 100 10 100 
P value 
ANOVA 
0.0000 
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Statistical Significance 
 
This indicates that there is a true difference among groups and the difference is 
significant. . In simple terms, when studying the association between flow 
mediated vasodilatation and coronary  angiographic changes, the LVEF% in 
non-critical CAD group is predominantly more(61%) when compared to SVD 
group(56,75%), DVD group(46.45) and TVD group(39,22). It is statistically 
significant with a p-value of 0.0000 according to ANOVA. 
 
Clinical Significance 
 
The average LVEF% in non-critical CAD group is meaningfully less than SVD 
group by 0.93 times with a mean difference of 4.25 percentage points. 
 
The average LVEF% in non-critical CAD group is meaningfully less than DVD 
group by 0.76 times with a mean difference of 14.55 percentage points. 
 
The average LVEF% in non-critical CAD group is meaningfully less than TVD 
group by 0.64 times with a mean difference of 21.78percentage points. 
 
This difference is true and significant and has not occurred by chance. 
 
Conclusion  
We conclude that there is meaningfully real increase in severity of CAD as 
LVEF% decreases in our study subjects.  
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By conventional criteria the association between the study groups and brachial 
artery resting diameter status is considered to be not statistically significant 
since p > 0.05. 
 
BRACHIAL 
ARTERY RESTING 
DIAMETER 
NORMAL 
Non Critical 
CAD 
SVD DVD TVD 
N 8 18 33 8 16 
MEAN 3.89 3.93 4.51 3.75 4.59 
SD 1.12 1.00 0.87 0.59 1.20 
BRACHIAL 
ARTERY 
RESTING 
DIAMETER 
Non 
Critical 
CAD 
% SVD % DVD % TVD % 
≤ 4 mm 14 78 9 27 5 63 9 56 
4 to 5 mm 1 6 12 36 3 38 1 6 
5 to 6  mm 2 11 11 33 0 0 3 19 
> 6 mm 1 6 1 3 0 0 3 19 
Total 18 100 33 100 8 100 16 100 
P value 
ANOVA 
0.092547156 
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By conventional criteria the association between the study groups and post 
occlusive diameter status is considered to be not statistically significant since p 
> 0.05. 
 
 
POST OCCLUSIVE 
DIAMETER 
Non Critical CAD SVD DVD TVD 
N 18 33 8 16 
MEAN 4.29 4.92 3.93 4.71 
SD 1.03 0.95 0.63 1.19 
POST 
OCCLUSIVE 
DIAMETER 
Non 
Critical 
CAD 
% SVD % DVD % TVD % 
≤ 4 mm 8 44 5 15 5 63 6 38 
4 to 5 mm 7 39 16 48 3 38 4 25 
5 to 6  mm 2 11 9 27 0 0 3 19 
> 6 mm 1 6 3 9 0 0 3 19 
Total 18 100 33 100 8 100 16 100 
P value 
ANOVA 
0.54579025 
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By conventional criteria the association between the study groups and increase 
in FMD among study subjects is considered to be statistically significant since p 
< 0.05.  
% INCREASE IN FMD Non Critical CAD SVD DVD TVD 
N 18 33 8 16 
MEAN 9.50 9.35 4.64 3.10 
SD 6.39 2.64 1.60 1.12 
% 
INCREASE 
IN FMD 
Non 
Critical 
CAD 
% SVD % DVD % TVD % 
≤ 7 % 8 44 8 24 8 100 16 100 
7.1 to 10 
% 
2 11 12 36 0 0 0 0 
10.1 to 15 
% 
3 17 13 39 0 0 0 0 
> 15 % 5 28 0 0 0 0 0 0 
Total 18 100 33 100 8 100 16 100 
P value 
ANOVA 
0.0000 
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Statistical Significance 
 
This indicates that there is a true difference among groups and the difference is 
significant. . In simple terms, when studying the association between flow 
mediated vasodilatation and coronary  angiographic changes, the increase in 
FMD  in non-critical CAD group is predominantly more (9.50%) when 
compared to SVD group(9.35%), DVD group(4.64) and TVD group(3.10). It is 
statistically significant with a p-value of 0.0000 according to ANOVA. 
 
Clinical Significance 
 
The average increase in FMD in non-critical CAD group is meaningfully less 
than SVD group by 1.02 times with a mean difference of 0.15 percentage 
points. 
 
The average increase in FMD in non-critical CAD group is meaningfully less 
than DVD group by 0.49 times with a mean difference of 4.86 percentage 
points. 
 
The average increase in FMD in non-critical CAD group is meaningfully less 
than TVD group by 0.33 times with a mean difference of 6,40 percentage 
points. 
This difference is true and significant and has not occurred by chance. 
  
Conclusion  
We conclude that there is meaningfully real increase in severity of CAD as the 
percentage increase in FMD decreases in our study subjects.   
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RESTING DIAMETER Vs FMD 
 
 
 
 
 
There is a negative correlation between resting diameter and FMD.  This is 
indicated by the Pearson's R Correlation value of -0.1869with a p-value of 
0.0000.  
This means as resting diameter increases the percentage increase in FMD 
decreases in our study subjects.  
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POST OCCLUSIVE DIAMETER Vs FMD 
 
 
 
 
 
 
Pearson’s Correlation(r) -0.0148 
P Value 0.0000 
 
There is a positive  correlation between post occlusion diameter and FMD.  This 
is indicated by the Pearson's R Correlation value of -0.0148with a p-value of 
0.0000.  
This means as post occlusion diameter increases the percentage increase in 
FMD increases in our study subjects.  
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CAG-
MODIFIED 
GENSINI 
SCORING 
NORMAL % 
NON 
OBS 
CAD 
% SVD % DVD % TVD % 
≤ 5 % 8 100 10 100 1 3 0 0 0 0 
5.1 to 10 % 0 0 0 0 8 24 0 0 0 0 
10.1 to 15 
% 
0 0 0 0 6 18 0 0 0 0 
> 15 % 0 0 0 0 18 55 8 100 16 100 
Total 8 100 10 100 33 100 8 100 16 100 
 
 
 
CAG-MODIFIED 
GENSINI 
SCORING 
NORMAL 
NON OBS 
CAD 
SVD DVD TVD 
N 8 10 33 8 16 
MEAN GENSINI 
SCORES 
0.00 2.30 19.45 39.94 57.38 
MEAN FMD % 9.6 9.5 9.35 4.64 3.1 
P value 
ANOVA 
0.0000 
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PEARSON’S CORRELATION  % INCREASE IN FMD 
CAG-MODIFIED 
GENSINI SCORING 
% INCREASE IN FMD 1  
CAG-MODIFIED GENSINI SCORING -0.474204513 1 
 
By conventional criteria the association between the study groups and Gensini 
scores among study subjects is considered to be statistically significant since p < 
0.05.  
 
 
Statistical Significance 
 
This indicates that there is a true difference among groups and the difference is 
significant. . In simple terms, when studying the carotid intima media 
thickness in assessing the severity of coronary artery disease, the Gensini 
scores in normal group (0) and non-obstructive CAD(2.3) group is 
predominantly less when compared to SVD group(19.45), DVD group(39.94) 
and TVD group(57.38). It is statistically significant with a p-value of 0.0000 
according to ANOVA. 
There is a strong negative correlation between increase in FMD % and Gensini 
scores. This is indicated by the Pearson's R Correlation value of -0.474204513. 
This means as increase in FMD % decreases the Gensini scores increases.  
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Clinical Significance 
 
The average Gensini scores in non-obstructive CAD group is meaningfully 
less than SVD group by 8.45 times with a mean difference of 17.15 scoring 
points. 
 
The average Gensini scores in non-critical CAD group is meaningfully less 
than DVD group by 17.36 times with a mean difference of 37.64 scoring 
points. 
 
 
The average Gensini scores in non-critical CAD group is meaningfully less 
than TVD group by 24.94 times with a mean difference of 55.08 scoring 
points 
 
The increase in increase in FMD % correlates negatively, directly and 
strongly with the Gensini scores. This means that the times of increase in 
average Gensini scores in comparision to CAD groupsis true 47.42 % of 
times 
 
 
This difference is true and significant and has not occurred by chance. 
 
Conclusion  
We conclude that there is meaningfully real increase in severity of CAD as 
Increase in FMD % decreases in our study subjects.   
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                           CITATIONS 
 
 MANGANARO et al  studied the endothelial dysfunction in patients with 
coronary artery disease in which 89 patients who underwent CAG were 
subjected to FMD and the severity of CAD was correlated with it . This 
study confirmed that FMD is reduced in patients with CAD and that such 
reduction in FMD is related to the extent of the disease. Therefore, FMD 
at the brachial artery is likely to represent a reliable indicator of CAD 
burden. 
 
 
 SHECHTER et al studied  the usefulness of brachial artery flow -
mediated vasodilatation to predict  the  long -term cardiovascular events 
in subjects without  cardiac disease . In conclusion, brachial artery 
median FMD independently predicts long-term adverse CV events in 
healthy subjects with no apparent heart disease in addition to those 
derived from traditional risk factor assessment. 
 
 CARERI G et al studied the clicinal correlation and prognostic value of 
FMD in patients with ACS. In conclusion, endothelial function is 
markedly impaired in the acute phase of (NSTEMI )ACS but improves 
significantly at 3-month follow-up. In patients with (NSTEMI )ACS, 
FMD at 3 months after the acute event is a significant independent 
predictor of cardiac outcomes. 
 
 KOYOSHI et al compared the clinical significance of FMD and CIMT in 
patients with and without coronary artery disease .The study concluded 
that FMD was a better predictor of  severity of CAD than CIMT 
 
 MUTLU B et al studied the usefulness of  FMD and CIMT in predicting 
occult CAD . FMD and CIMT might predict patients with occult CAD 
and be helpful in selecting patients for Multidetector row computed 
tomography (MDCT) 
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 LUO C studied the association of  FMD and highly sensitive C reactive 
protein with DUKE treadmill score(DTS) in patients with micro vascular 
angina. The results showed that FMD and C reactive protein correlate 
with DTS and useful in screening micro vascular  angina 
 
 BAMPI AB et al studied the comparisons between various non invasive 
methods for the detection of coronary artery disease .The results showed 
that it is possible to approximately determine the presence and extent of 
CAD by non-invasive methods, especially by  FMD ,calcium score, 
HDL-c and TG/HDL-c ratio assays 
 
 OZDEMIR AO studied the relation between FMD and coronary collateral 
circulation in a large cross sectional study . Results showed no significant 
association was found between the extent of angiographically 
visible coronary collaterals and systemic endothelial function assessed by 
FMD of the brachial artery. 
 
 VASILIEVA E et al studied the correlation of  FMD with total occlusion 
of  infarct related  coronary artery in patients with STEMI. The 
conclusions were that spontaneous coronary thrombolysis in patients with 
acute STEMI is associated with a preserved endothelium-dependent 
vasodilator response in the brachial artery. It can depend on the levels of 
hs-CRP, of fasting glucose, and of ACE-inhibitors from previous 
treatment. 
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                         CONCLUSION OF THIS STUDY 
               
Our aim of this study was to determine if there is any correlation between 
severity of CAD and FMD of the brachial artery , as well as to observe the 
relationship with various other cardiovascular risk factors . 
A total of  75 patients were included in the study and  following are  
conclusions from the statistical analysis. The subjects were divided into 4 four 
study groups as described above and subsequently analysed. 
 
 The association between the study group and factors like age , gender , 
diet ,alcohol intake ,duration  of hypertension was found to have no 
correlation  
 There is a positive correlation between duration of smoking and severity 
of  CAD  
 Presence of diabetes had an meaningful correlation with the study groups 
and there is a increase in severity of CAD with increase in duration of 
diabetes 
 BMI was found to have a positive correlation with the study groups and 
as the BMI of the patient increased  more severe was the CAD observed 
in them 
 Non HDL (LDL) was found to be the better marker for assessing the 
cardiovascular risk as there was a significant increase in CAD severity 
with increasing levels of LDL ,however no such positive correlation 
existed between study groups and HDL 
 Left ventricular ejection fraction measured at the time of admission was 
significantly lower as the severity of CAD increased  
 There was no positive correlation between  brachial artery resting 
diameter and post occlusive diameter among the various CAD groups 
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 Interestingly percentage of  increase in flow mediated vasodilatation 
correlated well with the severity of CAD , in which the more severe CAD 
patients had significantly lower percentage increase in FMD 
 There is also a meaningful correlation between   % increase in FMD and 
modified GENSINI SCORE.As the severity of CAD as assessed by 
modified GENISINI score increased significantly lower was the % 
increase in FMD. 
       
  Hence we conclude that apart from assessing the traditional 
cardiovascular risk factors , it is also important to assess the endothelial 
function of the patient by methods like FMD. It is very clear the 
physiological alteration(endothelial dysfunction)  in the body due to 
atherosclerosis, diabetes and other risk factors occur much before the 
structurally evident changes like plaques. FMD could be used as a tool to 
determine the endothelial function of the patients very early in the course 
natural history of CAD . Its use could be widely employed as it is non 
invasive and very simple procedure . Interestingly even unstable angina 
patients with normal /non obstructive CAG  had  endothelial dysfunction 
and whether this could be the reason for angina is still debatable. Since it 
a direct reflection of the health status of coronary vessels this could be 
utilised in screening of even young  healthy individuals with family 
history of CAD . This technique has great scope in the near future mainly 
because of its non invasive technique in assessing the severity of CAD. It 
however requires large sample studies to substantiate this and  though not 
yet recommended for routine clinical use, non invasive endothelial 
function testing has provided valuable insights into vascular changes 
associated with early atherosclerosis and the potential reversibility of 
arterial disease. 
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                                      PROFORMA 
 
PRELIMINARY DATA OF THE PATIENT : 
 
NAME : 
 
AGE 
 
SEX 
 
OP NO                                             IP NO 
 
PER CAPITA INCOME 
 
PHONE NUMBER 
 
CHIEF COMPLAINTS. 
 
 
CHEST PAIN 
 
SITE 
 
CHARACTER 
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RADIATION 
 
INTENSITY 
 
GRADE 
 
PALPITATION 
 
SYNCOPE 
 
GIDDINESS 
 
BLACKOUTS 
PAST HISTORY   
 
CAD  : 
TIA  : 
CVA  : 
PVD  : 
DM   :                                      TREATMENT  :          OHA  :                            
INSULIN  : 
SHT  :                                      TREATMENT  :           ON  :                              
OFF  : 
DYSLIPIDIMIA  : 
PCOD  : 
PERSONAL HISTORY  : 
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VEGETARIAN  :                                           NON VEGETARIAN  : 
 
SMOKING  :                   YES  :                    NUMBERS/ DAY              NO   
DURATION               
< 5     5 – 10    > 10 
                                        BEDI  : 
                                        CIGARETTE  : 
 
ALCOHOLIC                   YES  : NO  :ML / DAY 
 
ILLICIT DRUG USE         YES                           NO  : 
 
FAMILY HISTORY  : 
 
MENSTRUAL HISTORY  : 
 
TREATMENT HISTORY  : 
 
HEPARINISED OR NOT 
THROMBOLYSED OR NOT  : 
ANTI DYSLIPIDIMICS  : 
GENERAL EXAMINATIONS 
CONSIOUS/ ORIENTED/ COMFORTABLE 
DYSPNEA 
JVP 
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PALLOR/ CYANOSIS/ CLUBBING/ PEDAL EDEMA 
                                                           YES  :                   NO  : 
 
 
ARCUS SENILIS                         
TENDON XANTHOMA 
ERRUPTIVE XANTHOMA 
TUBO ERRUPTIVE XANTHOMA 
HEIGHT 
WEIGHT 
BMI 
WAIST HIP RATIO 
 
 
 
SYSTEMIC EXAMINATION 
 
CVS 
 
RS 
 
P/ A 
 
CNS 
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INVESTIGATIONS 
 
FBS         < 110      111 – 126     >126 
 
PPBS       <140       141 – 200    > 200 
FLP 
TFT 
SERUM FIBRINOGEN 
SERUM CALCIUM 
CRP 
ECG 
CARDIAC MARKERS 
ECHO  -  AV SCLEROSIS 
TMT 
USG ABDOMEN 
CIMT 
CAG 
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GOVT.STANLEY MEDICAL COLLEGE, CHENNAI- 600 001 
 
INFORMED CONSENT 
 
DISSERTATION TOPIC: “A STUDY ON USEFULNESS OF FLOW MEDIATED VASODILATATION 
OF BRACHIAL ARTERY  IN ASSESSING THE SEVERITY OF CORONARY ARTERY DISEASE 
AND ITS CORRELATION WITH CORONARY ANGIOGRAM” 
 
PLACE OF STUDY: GOVT. STANLEY MEDICAL COLLEGE, CHENNAI 
 
NAME AND ADDRESS OF PATIENT: 
 
I, _____________________ have been informed about the details of the study in my own 
language. 
 
I have completely understood the details of the study. 
 
I am aware of the possible risks and benefits, while taking part in the study. 
 
I understand that I can withdraw from the study at any point of time and even then, I will 
continue to receive the medical treatment as usual. 
 
I understand that I will not get any payment for taking part in this study. 
 
I will not object if the results of this study are getting published in any medical journal, 
provided my personal identity is not revealed. 
 
I know what I am supposed to do by taking part in this study and I assure that I would 
extend my full co-operation for this study. 
 
 
Name and Address of the Volunteer:  
 
Signature/Thumb impression of the Volunteer 
Date: 
Witnesses:  (Signature, Name & Address) 
Date: 
Name and signature of investigator:                    
Date: 
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ப்ரக்கியல் தமனியின் விரிவு தன்மமமய அளப்பதின் முலம் கரரோனரி 
தமனி இதயர ோய் தீவரீத்மதயும்மற்றும் கரரோனரி ஆஞ்சிரயோகிரோம் 
உடன் ஒப்பிட்டுபோர்க்கும் ஒரு ஆய்வு 
ஆய்வாளர்:மரு.  . ரரந்திரன்.அ, 
துநிலைபட்டமேற்படிப்புோணவர், 
ப ொதுமருத்துவபட்டபடிப்பு. 
வழிகாட்டி:பேராசிரியர்மரு.க தமிழ்பெல்வன் 
ப ொதுமருத்துவமபராசிரியர், 
அரசுஸ்டான்ைிேருத்துவேலை. 
சுயஒப்புதல்ேடிவம் 
பபயர்:                                     வயது:                    உள்ளிருப்புஎண்: 
இந்தேருத்துவஆய்வின்விவரங்கள்எைக்குவிளக்கப்பட்டது.என்னுலடயசந்மதகங்கலளக்மகட்கவும்,அதற்
காைதகுந்தவிளக்கங்கலளப்பபறவும்வாய்ப்பளிக்கப்பட்டது. 
நான்இவ்வாய்வில்தன்ைிச்லசயாகத்தான்பங்மகற்கிமறன்.எந்தகாரணத்திைாலும்,எந்தகட்டத்திலும்,எந்தசட்
டசிக்கலும்இன்றிஇந்தஆய்விைிருந்துவிைகிக்பகாள்ளைாம்என்றும்அறிந்துபகாண்மடன். 
நான்ஆய்விைிருந்துவிைகிக்பகாண்டாலும்ஆய்வாளர்என்னுலடயேருத்துவஅறிக்லககலளப்பார்ப்பதற்மகா
அல்ைதுஉபமயாகிக்கமவாஎன்அனுேதிமதலவயில்லை எைவும் 
அறிந்துபகாண்மடன்.என்லைப்பற்றியதகவல்கள்இரகசியோகப்பாதுகாக்கப்படும்என்பலதயும்அறிமவன். 
இந்தஆய்வின்மூைம்கிலடக்கும்தகவல்கலளயும்பரிமசாதலைமுடிவுகலளயும்.ஆய்வாளர்அவர்விருப்பத்தி
ற்மகற்பஎவ்விதோகப்பயன்படுத்திக்பகாள்ளவும்,அதலைபிரசுரிக்கவும்முழுேைதுடன்சம்ேதிக்கிமறன். 
இந்தஆய்வில்பங்குபகாள்ளஒப்புக்பகாள்கிமறன்.எைக்குபகாடுக்கப்பட்டஅறிவுலரகளின்படிநடந்துபகாள்வ
துடன், 
ஆய்வாளருக்குஉண்லேயுடன்இருப்மபன்என்றும்உறுதியளிக்கிமறன்.என்உடல்நைம்பாதிக்கப்பட்டாமைாஅ
ல்ைதுவழக்கத்திற்குோறாைமநாய்க்குறிபதன்பட்டாமைாஉடமைஅலதபதரிவிப்மபன் எை 
உறுதிகூறுகிமறன். 
இந்தஆய்வில்எைக்கு எவ்விதோை 
பரிமசாதலைகலளயும்,சிகிச்லசகலளயும்மேற்பகாள்ளநான்முழுேைதுடன்சம்ேதிக்கிமறன். 
இப்படிக்கு 
மநாயளியின்லகபயாப்பம்     ஆய்வாளர்லகபயாப்பம்/பபயர் 
 
                          
(பபயர்:                 ) 
 
(ேரு..)  ரரந்திரன்.அ, 
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ப்ரக்கியல்தமனியின்விரிவுதன்மமமயஅளப்பதின்முலம்கரரோனரிதமனி
இதயர ோய்தீவரீத்மதயும்மற்றும்கரரோனரிஆஞ்சிரயோகிரோம்உடன்ஒப்பிட்
டுபோர்க்கும்ஒருஆய்வு 
ஆய்வாளர்:மரு. ரரந்திரன்அ, 
முதுநிலைபட்டமேற்படிப்புோணவர், 
ப ொதுமருத்துவபட்டபடிப்பு. 
வழிகாட்டி:பேராசிரியர்மரு.கதமிழ்பெல்வன் 
ப ொதுமருத்துவமபராசிரியர், 
அரசுஸ்டான்ைிேருத்துவேலை. 
 
ேங்பேற்ோளரின்தேவல்ேடிவம் 
நீங்கள்இந்தஆய்வில்பங்மகற்க அலழக்கப்படுகிறரீ்கள். இந்தஆய்வில்பங்மகற்கும்முன், 
இதன்மநாக்கத்லதயும்,முலறகலளயும்,இதைால்ஏற்படும்பின்விலளவுகலளயும்நீங்கள்அறிந்துபகாள்ளஆ
ய்வாளர்அளிக்கும்தகவல்: 
உங்கள்மநாயின்வரைாறும்,உங்களின்முழுஉடல்பரிமசாதலையும்பதளிவாகவும்விரிவாகவும்பதிவுபசய்யப்
படும். 
இந்தஆய்வின்முடிவுகள்ேருத்துவகாரணங்களுக்காகவும்,ேருத்துவகல்விக்காகவும்பயன்படுத்தப்படும்.இந்
தஆய்வுபற்றியசந்மதகங்களுக்குஉரியமுலறயில்விளக்கேளிக்கப்படும்.தங்கலளப்பற்றியதகவல்கள்இரகசி
யோகபாதுகாக்கப்படும். 
இந்தஆய்வில்இருந்துஎப்மபாதுமவண்டுோைாலும்தாங்கள்எவ்விதமுன்ைறிவிப்பின்றியும், 
எவ்விதசட்டசிக்கலும்இன்றிவிைகிக்பகாள்ளைாம். 
இந்தஆய்வில்பங்மகற்குோறுமகட்டுக்பகாள்கிமறன். 
நன்றி, 
 
ஆய்வாளர் லகபயாப்பம்      மநாயாளியின் லகபயாப்பம் 
( ேரு.)  ரரந்திரன்அ(பபயர்:                 ) 
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                                MASTER KEY CHART 
 
AGE SEX SMO NV HT DM BMI SADTSFTSAD/TSFTSBP DBP LDL HDL LVEF(%) DIAGCIMT(mm)BAD1 BAD2 %BAD CAG GEN
55 M YES,10 YRS YES NO NO 23.712 140 110 95 36 40 AWMI 4.4 4.8 9.1 SVD 24
55 M NO YES NO NO 20.449 130 80 90 35 53 IW+PW+RVMI 3.5 3.6 2.9 TVD 46
60 M YES,20 YRS YES NO NO 21.193 100 60 92 30 42 AWMI 3.1 3.3 6.5 DVD 31
48 M YES,40 YRS YES NO NO 24.442 130 80 89 39 45 ASMI 4.2 4.7 11.9 SVD 4
45 M YES,15 YRS YES NO NO 29.017 120 80 120 32 45 AWMI 4.5 4.8 6.7 SVD 48
35 M YES,10YRS YES NO NO 21.517 140 90 105 34 42 EXT AWMI 3.1 3.2 3.2 DVD 92
46 M YES,20YRS YES NO NO 24.539 140 80 110 32 55 UA 4.1 4.2 2.5 NORMAL 0
58 F NO YES YES,3YRS YES,6 MON 30.252 110 70 98 42 60 NSTEMI 3.2 3.7 15 NON OBS CAD 2
48 F NO YES NO NO 26.896 120 80 85 45 60 NSTEMI 3.4 3.5 2.99 NORMAL 0
39 F NO YES YES,6YRS YES,6YRS 32.895 110 80 105 33 60 EA-CLASS 3 3.2 3.36 12.5 SVD 24
50 M NO YES NO YES,3YRS 27.435 120 90 80 41 33 AWMI 3.7 3.8 2.8 TVD 68
54 F NO NO NO YES,3YRS 30.252 120 80 86 40 62 UA 2.9 3 3.45 NORMAL 0
58 F NO YES YES,10YRS NO 27.111 150 70 89 50 60 NSTEMI 3.8 4 5.3 DVD 21
55 F NO YES YES,10YRS YES,5YRS 29.728 150 100 90 40 60 NSTEMI 3.6 4.2 16.1 NON OBS CAD 4
56 F NO YES YES,3YRS YES,5YRS 31.626 120 80 92 37 64 EA-CLASS 3 3.4 3.9 14.8 NON OBS CAD 2
59 M yes,3YRS YES YES,1YR YES,1YR 25.217 130 80 89 52 60 UA 5.9 6 1.7 NON OBS CAD 2.5
55 M NO NO NO NO 22 130 80 87 43 50 UA 3.9 4.6 17 NON OBS CAD 1
59 M YES,50YRS YES NO NO 26.026 120 70 99 38 54 IW+PWMI 4.3 4.4 2.32 DVD 84
36 M YES,20YRS YES NO NO 27.64 120 70 99 45 45 ASMI 5.1 5.6 9.8 SVD 12
38 M YES,10YRS YES NO NO 20.957 110 70 87 42 50 ASMI 6.4 6.9 7.81 NORMAL 0
35 M NO NO NO NO 23.111 120 80 95 39 45 IW+PWMI 4.5 5 11 SVD 6
50 M YES,30YRS YES NO NO 24.977 120 80 110 46 45 ASMI 6 6.6 10 SVD 24
40 F NO YES NO YES,3YRS 37.195 190 110 104 40 41 ASMI 4.5 4.8 6.66 SVD 40
50 M NO YES YES,1YR NO 28.134 100 70 83 46 45 IWMI 5.42 6 11.2 SVD 8
57 M NO YES YES,6MONTHS YES,18YRS 27.734 140 90 88 48 40 AWMI 5.1 5.4 5.9 SVD 12
60 M YES,10YRS YES NO YES,2YRS 30.405 140 90 108 50 48 NSTEMI 4.1 4.6 12.2 SVD 6
58 M YES,25YRS YES NO YES,10YRS 22.862 150 80 91 46 42 UA 6.5 6.6 3.07 TVD 48
59 M NO YES YES,5YRS NO 25.217 120 80 87 43 40 AWMI 5.5 5.6 1.81 TVD 17
52 M YES,5YRS YES NO NO 19.607 140 80 105 48 40 AWMI 3 3.4 13.3 SVD 10
50 M YES,32YRS YES NO YES,2YRS 22.719 130 80 104 50 48 IW+PWMI 4 4.2 5.1 TVD 22
55 M NO YES YES,5YRS NO 26.037 120 60 108 47 62 AWMI 4 4.1 2.5 TVD 34
57 F NO NO NO YES,5YRS 25.3 136 70 104 43 56 UA 4 4.2 5.1 SVD 16
47 F NO YES YES,3YRS YES,4YRS 26.3 124 86 85 37 43 AWMI 5.1 5.6 9.8 SVD 24
45 M yes 20 yrs YES NO NO 24.5 130 90 96 34 38 AWMI 4.5 4.8 6.66 DVD 34
56 F NO YES YES 2YRS YES 5YRS 25.5 120 80 95 34 53 AWMI 3.5 3.6 2.8 TVD 54
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65 M YES 15 YRS YES NO YES 10YRS 25.6 110 70 92 36 42 IW+PW+RVMI 3.1 3.2 3.2 TVD 58
53 M YES,40 YRS YES YES 6 YRS NO 25.6 130 80 95 33 45 ASMI 4.2 4.8 14.28 SVD 14
45 M YES,15 YRS YES NO NO 29.017 120 80 120 32 45 AWMI 4.5 4.8 6.7 SVD 48
35 M YES,10YRS YES NO NO 21.517 140 90 105 34 42 EXT AWMI 3.1 3.2 3.2 DVD 92
46 M YES,20YRS YES NO NO 24.539 140 80 110 32 55 EXT AWMI 4.1 4.2 2.5 TVD 48
58 F NO YES YES,3YRS YES,6 MON 30.252 110 70 98 42 60 NSTEMI 3.2 3.7 15 NON OBS CAD 2
48 F NO YES NO NO 26.896 120 80 85 45 60 NSTEMI 3.4 3.5 2.94 NORMAL 0
60 F NO YES YES,6YRS YES,6YRS 32.895 110 80 105 33 60 EA-CLASS 3 3.2 3.36 12.5 SVD 24
50 M NO YES NO YES,3YRS 27.435 120 90 80 41 33 AWMI 3.7 3.8 2.8 TVD 68
44 M NO NO YES 5YRS YES,3YRS 29.5 160 90 96 36 35 UA 2.9 3.1 6.9 NORMAL 0
58 F NO YES YES,10YRS NO 27.111 150 70 89 50 60 NSTEMI 3.8 4 5.3 DVD 21
55 F NO YES YES,10YRS YES,5YRS 29.728 150 100 90 40 60 NSTEMI 3.6 4.2 16.1 NON OBS CAD 4
58 F NO YES YES,3YRS YES,5YRS 31.626 120 80 92 37 64 EA-CLASS 3 3.4 4 17.6 NON OBS CAD 2
59 M yes,3YRS YES YES,1YR YES,1YR 25.217 126 84 86 45 60 UA 5.5 6 9.09 NON OBS CAD 2.5
55 M NO NO NO NO 22 130 80 87 43 50 UA 3.9 4.6 17 NON OBS CAD 1
57 M YES,50YRS YES NO NO 26.026 120 70 99 38 54 IW+PWMI 4.3 4.5 4.65 DVD 84
36 M YES,20YRS YES NO NO 27.64 120 70 99 45 45 ASMI 5.1 5.6 9.8 SVD 12
38 M YES,10YRS YES NO NO 20.957 110 70 87 42 50 ASMI 6.4 6.9 7.81 SVD 28
35 M NO NO NO NO 23.111 120 80 95 39 45 IW+PWMI 4.5 5 11 SVD 6
50 M YES,30YRS YES NO NO 24.977 120 80 110 46 45 ASMI 6 6.6 10 SVD 24
40 F NO YES NO YES,3YRS 37.195 190 110 104 40 41 ASMI 4.5 4.8 6.66 SVD 38
50 M NO YES YES,1YR NO 28.134 100 70 83 46 45 IWMI 5.42 6 11.2 SVD 8
45 M NO YES YES,6MONTHS YES,18YRS 27.734 140 90 88 48 40 AWMI 5.1 5.4 5.9 SVD 12
59 M YES,10YRS YES NO YES,2YRS 30.405 140 90 108 50 48 NSTEMI 4.1 4.6 12.2 SVD 6
58 M YES,25YRS YES NO YES,10YRS 22.862 150 80 91 46 42 UA 6.5 6.6 3.07 TVD 46
59 M NO YES YES,5YRS NO 25.217 120 80 87 43 40 AWMI 5.5 5.6 1.81 TVD 17
52 M YES,5YRS YES NO NO 19.607 140 80 105 48 40 AWMI 3 3.4 13.3 SVD 12
50 M YES,32YRS YES NO YES,2YRS 22.719 130 80 104 50 48 IW+PWMI 4 4.2 5.1 TVD 22
55 M NO YES YES,5YRS NO 26.037 120 60 108 47 62 UA 4 4.1 2.5 NORMAL 0
57 F NO NO NO YES,5YRS 25.3 136 70 104 43 56 UA 4 4.2 5.1 SVD 16
47 F NO YES YES,3YRS YES,4YRS 26.3 124 86 85 37 43 AWMI 5.1 5.6 9.8 SVD 24
60 M YES,25YRS YES NO YES,10YRS 22.862 150 80 91 46 42 UA 6.5 6.6 3.07 TVD 52
59 M NO YES YES,5YRS NO 25.217 120 80 87 43 40 AWMI 5.5 5.6 1.81 TVD 17
52 M YES,5YRS YES NO NO 19.607 140 80 105 48 40 AWMI 3 3.4 13.3 SVD 10
50 M YES,32YRS YES NO YES,2YRS 22.719 130 80 104 50 48 IW+PWMI 3.8 4 5.26 TVD 22
55 M NO YES YES,5YRS NO 26.037 120 60 108 47 62 UA 4 4.1 2.5 NORMAL 0
57 F NO NO NO YES,5YRS 25.3 136 70 104 43 56 UA 4 4.3 7.5 SVD 18
47 F NO YES YES,3YRS YES,4YRS 26.3 124 86 85 37 43 AWMI 5.1 5.6 9.8 SVD 26
40 F NO YES NO YES,3YRS 37.195 190 110 104 40 41 ASMI 4.5 4.9 8.9 SVD 42
45 F NO NO NO YES,5YRS 25.3 136 70 104 43 56 UA 4 4.3 7.5 SVD 16
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                                      KEY TO MASTERCHART 
 
 
NV – NON VET DIET 
HT – HYPERTENSION 
DM – DIABETES 
BMI – BODY MASS INDEX 
SBP – SYSTOLIC BLOOD PRESSURE 
DBP – DIASTOLIC BLOOD PRESSURE 
LDL – LOW DENSITY LIPOPROTEIN 
HDL – HIGH DENSITY LIPOPROTEIN 
CAG – CORONARY ANGIOGRAM 
LVEF – LEFT VENTRICULAR EJECTION FRACTION 
BAD1 – BRACHIAL ARTERY DIAMETER PRE DILATATION 
BAD2 – BRACHIAL ARTERY DIAMETER POST DILATATION 
%BAD – PERCENTAGE INCREASE IN BRACHIAL ARTERY DIAMETER 
GEN - MODIFIED GENSINI SCORE 
SVD – SINGLE VESSEL DISEASE 
DVD – DOUBLE VESSEL DISEASE 
TVD – TRIBLE VESSEL DISEASE 
NON OBS – NON OBSTRUCTIVE CAD 
UA – UNSTABLE ANGINA 
 
 
